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Abstract 
 
Background 
One of the problems with colonoscopy is its imperfection due to variation in 
operator dependent adenoma detection rates. Low adenoma detection rates are 
linked to increased interval colorectal cancer rates and reduced cancer survival. 
  
 
7 
Devices to enhance mucosal visualisation and improve adenoma detection rates 
such as Endocuff Vision have been developed. The primary aim of this study 
was to compare adenoma detection rates between Endocuff Vision-assisted 
colonoscopy and standard colonoscopy. 
 
Methods 
 A multicentre, randomised controlled trial in seven hospitals in the United 
Kingdom was undertaken. Patients aged 18 and above referred for colonoscopy 
due to symptoms, colonoscopy surveillance, or as part of the Bowel Cancer 
Screening Programme following a positive screening faecal occult blood test 
were invited to the study. Patients with a suspicion of bowel obstruction, 
known colon cancer, polyposis syndromes, known strictures, active colitis, on 
anticoagulant therapy during the procedure, pregnant, attending for a 
therapeutic procedure or assessment of a known lesion were excluded.  
 
Findings 
One thousand, seven hundred and seventy-two patients (57% male, mean age 
62) were recruited from November 2014 until February 2016. Patient 
characteristics were comparable between trial arms. Endocuff Vision increased 
adenoma detection rates by 4.7% (p=0.02). This was largely driven by an 
increase in adenoma detection rates in screening patients from 50.9% to 61.7% 
(p<0.001). Endocuff Vision-assisted colonoscopy also detected more mean 
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adenomas per procedure, left sided adenomas, sessile serrated adenomas, 
diminutive adenomas, small adenomas and cancers. Cuff removal rate was 4.1%. 
Median intubation time was one minute quicker with Endocuff Vision- assisted 
colonoscopy (p=0.001). Anal intubation was rated as more uncomfortable with 
Endocuff Vision-assisted colonoscopy. There were no significant cuff-related 
adverse events. Endocuff Vision- assisted colonoscopy was non-inferior to SC in 
other markers of comfort and procedure time. 
 
Conclusion 
Endocuff Vision significantly improved ADR driven by an improvement in the 
faecal occult blood test positive screening population. Endocuff Vision-assisted 
colonoscopy was non-inferior in all aspects other than discomfort on anal 
intubation.  
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Introduction 
 
Colorectal cancer is the second most common cause of cancer related death in 
Europe and North America and is the third most common cancer in the world. 
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In the United Kingdom, it is the fourth most common cancer with 41,000 cases 
diagnosed annually. Five decades ago, the link between adenomas and 
colorectal cancer was established with emerging evidence that the risk of 
colorectal cancer decreased if some adenomas were removed at the early stages. 
Adenomas are benign polyps found in up to a third of the Western population 
over fifty. Adenoma detection rate (ADR) is defined as the percentage of 
patients in whom at least one adenoma is identified. This can vary per patient 
or endoscopy group.   
 
Colonoscopy is the accepted state-of-the-art investigation of the colon, as it not 
only allows for an examination but also removal of polyps and biopsy sampling. 
However, it is imperfect and only reduces the risk of colorectal cancer by 50% 
owing to missed adenomas. A standard colonoscope has a forward-facing fibre 
optic camera at the tip and is used to provide mucosal views of the bowel wall 
as the instrument is withdrawn. However, adenomas that are small, flat or 
present in difficult corners between mucosal folds can be missed. There are up 
to 360,000 colonoscopies performed per year in the United Kingdom and this 
number is rising. The rate of colonoscopies performed increased from 194 to 
329 procedures per 10,000 patients from 2011 to 2012. This rising demand 
against the backdrop of restricted capacity and National Health Service budget 
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freeze makes it vital that each procedure is performed to the highest standard 
possible.  
 
Endoscopy is unique in that it is a procedure that can be carried out by various 
clinicians including specialist nurses, general practitioners with special 
interests, gastroenterologists and surgeons. However, standards of colonoscopy 
and ADR can vary widely between groups of colonoscopists. Despite Bowel 
Cancer Screening Programme (BCSP) colonoscopists having a high ADR when 
compared with other groups of colonoscopists, many devices and technological 
advances created to improve ADR are only being used or tested by BCSP 
colonoscopists. What is required is an intervention that will improve ADR 
across all groups of colonoscopists as this will be a more accurate reflection of 
the general population of colonoscopists and have a larger, more realistic 
impact on improving ADR in the UK.    
 
The National Bowel Cancer Audit Annual Report, 2013, found that the rate of 
emergency admissions with colorectal cancer has remained stagnant at 21-22% 
since 2008 despite Bowel Symptom Awareness and the Bowel Screening 
Programme. The mortality rate for colorectal cancer has remained at 18 in 
100,000 people since 2003. The evidence is that patients who present as 
emergencies perform poorly when compared with patients undergoing a 
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planned elective operation. Although many factors can be attributed to this, it 
could be deduced that interval colorectal cancers from missed adenomas 
contribute to this percentage.     
 
During my training as a specialist trainee in colorectal surgery, I have 
experienced first hand how early detection of colorectal cancers can have a 
substantial improvement on patient outcomes. Early cancers are easier to 
remove surgically as they are often less bulky, localised and require less radical 
resection. Patients are more likely to be offered laparoscopic surgery resulting 
in less postoperative pain, reduced complications and shortened overall 
hospital stay. One could even argue that ‘early cancers’ are removed by 
colonoscopists without the need for any surgical intervention. Early detection 
of colorectal cancer relies on a chain of events occurring successfully, from 
patient recognition of signs and symptoms to seeking medical attention to 
having appropriate investigations. Improving the quality of colonoscopy is only 
a cog in the wheel of this pathway.  
 
It is timely that numerous devices are now being tested with the aim of 
increasing ADR. One such device is Endocuff Vision, which is used in this trial. 
This thesis aimed to address the use of an add-on endoscopic device called 
Endocuff Vision in improving adenoma detection rate. This will benefit patients 
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resulting in a more accurate examination with lower rates of missed polyps and 
ensure that the most accurate endoscopic surveillance programme is selected. 
It will also benefit NHS and other healthcare providers as there will be a 
reduced risk due to fewer missed polyps and improved ADR with a potential 
correlating reduction in interval colorectal cancers. This will be explored in 
more detail by means of a literature review. 
  
 
 
 
 
 
 
 
 
 
 
 
Chapter 1: A Review of the Literature 
 
1.1 Background: Adenomas and colorectal cancer in the United 
Kingdom 
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1.1.1 Epidemiology 
 
Colorectal cancer (CRC) is the third most common cancer in the world with 1.4 
million new cases diagnosed annually 1. In the United Kingdom (UK), CRC is 
the fourth most common cancer. In 2014, there were 41,265 new cases with the 
majority affected being male 2. There are 72 and 56 new cases of colon cancer 
for every 100,000 male and female in the UK respectively 2. A majority (90%) of 
colorectal cancers are adenocarcinoma that arise from colorectal adenomas. 
Colorectal adenomas are common and are present in a third of European and 
American populations 3. 
 
Colorectal cancer is the second most common cause of cancer related death in 
the UK and accounts for 10% of all cancer deaths 2. In 2014, there were 15,903 
deaths attributed to colorectal cancer: 54% in males and 46% in females 2. The 
2-year overall survival rate of colorectal cancer is 67%. The 2-year survival rate 
in patients with major resection and associated oncologic therapy is 80% but in 
those with no major resection this figure falls to 45% 4. The net colorectal 
cancer survival rate for both sexes is 76% at one year, 59% at five years and 57% 
at ten years 5. Interestingly, the five year net survival ranges from 65% (60-69 
year olds) to 43% (80-99 year olds) in males and 66% (60-69 year olds) to 43% 
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(80-99 year olds) in females 6. This is probably explained by the availability of 
bowel cancer screening in the 60-69 year age group.  
 
Colorectal cancer is more common on the left side of the colon with 75% of 
cancers occurring at or distal to the splenic flexure 2. In this group, patients 
often present with abdominal pain, a change in bowel habit or rectal bleeding 7. 
On the other hand, cancers proximal to the splenic flexure present with less 
apparent symptoms.  
 
The diagnosis of CRC is often made when the disease has progressed to a more 
advanced stage, resulting in poorer clinical outcomes. Patients diagnosed with 
the earliest stages of the disease (Dukes A) have a 5-year survival rate of 93.2% 
compared to patients diagnosed with advanced disease (Dukes C) with a 5-year 
survival rate of 6.6% 8. 
 
 
 
 
 
1.1.2 The adenoma-carcinoma sequence 
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Cancers are formed through accumulation of mutations in key genes that are 
responsible for regulating cell growth 9. This was theorised to happen in three 
steps – initiation, promotion and progression 10. Specific to colonic epithelium, 
there is a disciplined progression of genetic events with corresponding 
histological abnormalities that lead to colorectal cancer 11.  
 
Most cancers are made up of cells that have pro-tumorigenic mutations which 
are unable to cause morphological change but do predispose to malignancy 12,13. 
Adenomas are a type of colorectal polyp that have the potential to undergo 
malignant transformation 14. The adenoma-carcinoma sequence is the pathway 
by which adenomatous polyps develop into colorectal cancer 15,16. It is the 
progression of normal epithelium to dysplastic to malignant based on the 
accumulation of multiple genetic mutations. Figure 1 illustrates the various 
stages of the adenoma-carcinoma sequence 17.  
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  Figure 1: Adenoma-carcinoma sequence 17 
 
Many different factors are responsible for the development of adenomas. These 
factors can be classified into modifiable and non-modifiable risk groups. 
Modifiable risk factors include body mass index, alcohol intake, smoking status 
and diet. Non-modifiable risk factors include gender, age and genetic factors. 
Other concurrent medical disorders including diabetes, inflammatory bowel 
disease and obesity also predispose an individual to adenoma formation 18–20. 
Good lifestyle advice and modification together with optimisation of medical 
conditions may reduce the risk of adenomas. However, there is currently not 
enough evidence to support this.   
Thus, another angle of approach is prevention of colorectal cancer by 
endoscopic removal of precursor lesions such as adenomas. This is a strategy 
that increasing in popularity as there is evidence that the incidence of CRC in 
patients with complete colonoscopy and adenoma removal is significantly 
lower compared with matched cohorts 21.  
 
On the other hand, the correct management of patients with precursor lesions 
such as adenomas is crucial. Studies have shown that up to 35% of patients who 
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have had adenomas removed will develop further adenomas in 3-4 years 22,23. 
Thus, most guidelines advocate a policy of endoscopic surveillance for patients 
found to have adenomas. The British Society of Gastroenterology guidelines 
divide patients into three risk groups based on the number and size of 
adenomas found to determine colonoscopic surveillance 24.  However, as only a 
third of the Western population will go on to develop adenomas with only 3% 
suffering from colorectal cancer; it seems that only a small proportion of 
adenomas progress to malignancy 15.  
 
There is wealth of literature in favour of the adenoma-carcinoma sequence 
based on epidemiological, clinicopathological and genetic factors 15. The 
prevalence of adenomas and cancer increase with age but adenoma prevalence 
increases at least 5 years before that of colorectal cancer 16. Studies have also 
demonstrated histopathologically that in up to 6% of cases, colorectal 
adenomas have been found to contain a focus of malignancy 25. Equally, 
adenomatous tissue has also been identified in up to 23% of colorectal cancer 
specimens 16,26 and there is an increased incidence of malignant cells in 
adenomas of a larger size 27. In addition, adenomas are encountered more 
frequently in patients with synchronous primary cancers 28. Anatomically, the 
distribution of colorectal adenomas is similar to cancers; both presenting more 
frequently in the left colon 29,30. A large randomised controlled trial with a 
follow up period of 18 years illustrated that faecal occult blood testing 
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significantly reduced the incidence of colorectal cancer with this being 
attributed to the fact that adenomatous polyps would have been identified and 
removed in this group leading to a reduction in overall cancer incidence 31.  
 
1.1.3 The role of colonoscopy in detecting colorectal cancer 
 
Colonoscopy has been available since the 1960s when it was first developed by 
Dr William Wolff and Dr Hiromi Shinya 32. Prior to this, clinicians were relying 
on the use of barium enema and sigmoidoscopy to assess the colon but this was 
quickly superseded by the colonoscope which allowed for direct visualisation of 
the colon, biopsy sampling and removal of polyps 32. Colonoscopy is currently 
the accepted investigation of choice for the detection of colonic pathology. It 
provides clinicians with the ability to establish a diagnosis, sample colonic 
tissue and perform therapeutic procedures. 
Nevertheless, despite the benefits of a colonoscopy, it remains an invasive 
procedure that is not without risk. Patients are required to undergo bowel 
preparation, which involves tolerating a fluid diet and drinking large amounts 
of laxatives. It is an uncomfortable procedure and in the UK, most patients are 
offered the choice of mild sedation and analgesia in the form of pethidine, 
fentanyl, midazolam or an analgesic gas containing 50% nitrous oxide and 50% 
oxygen (Entonox). In addition, most units subscribe to the use of hyoscine-n-
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butylbromide. Most of these prescribed medications have rare side effects that 
can be life threatening.  
 
There are also associated risk of complications occurring because of the 
procedure with the most severe being risk of bleeding (1.64/1000) and risk of 
bowel perforation (0.85/1000) 33. Post polypectomy complication rates have 
been quoted at 7 per one thousand tests 34.  
 
Current alternatives to colonoscopy include barium enema, virtual colonoscopy 
and more recently, colon capsule endoscopy. Barium enema is a radiological x-
ray examination that involves the injection of a contrast agent like barium 
sulphate into the rectum. It carries a risk of radiation exposure and bowel 
perforation. The sensitivity of barium enema at 83% is lower than the 
sensitivity of colonoscopy at 95% at detecting colorectal cancer 35. The polyp 
detection rate of barium enema is reported to be 38% compared to the polyp 
detection rate of 80% in patients with colonoscopy 36.  
 
Virtual colonoscopy or Computed Tomography colonography produces a 3-
dimensional model of the colon that can digitally detect polyps. It requires no 
sedation and is none invasive thus avoiding major complications of bleeding 
and perforation. However, bowel preparation is still required and any polyps 
detected would still need to be removed by a colonoscopy. There is also a small 
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risk of radiation exposure which might predispose to more cancers 30. The 
sensitivity of virtual colonoscopy in detecting colorectal lesions has been 
reported at 73% when compared to colonoscopy 37.  
 
In capsule endoscopy, patients are required to swallow a small pill equipped 
with a camera that travels into the bowel to collect images. It was first used 
primarily for small bowel imaging in occult bleeding and has been very 
successful in that aspect. However, advances in capsule technology have 
allowed for its use in colon imaging with the second generation of colon 
capsule endoscopy – PillCam Colon 2 being made available. Early studies 
suggest that it has a role in cases of colonoscopy failure, in patients unwilling to 
undergo colonoscopy, in cases when colonoscopy is contraindicated and 
potentially in colorectal cancer screening or surveillance of inflammatory bowel 
disease patients 38. Interestingly, Japanese researchers have begun 
experimenting with a magnetic navigation system which when used together 
with colon capsule endoscopy aim to provide a less invasive method of 
potentially investigating the whole gastrointestinal tract. In their small pilot 
study, they illustrated a completion rate of 97.5% 39. A recent prospective 
Japanese trial of 66 patients evaluated the sensitivity of colon capsule 
endoscopy and found that it had a high sensitivity of 94% in detecting 
significant colonic lesions when followed by standard colonoscopy 40. Although 
this may have been elevated in part because all patients had known colonic 
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lesions, this study is promising and illustrates that colon capsule endoscopy is 
safe with a high level of patient acceptability. However, capsule endoscopy does 
not allow for biopsy, removal of lesions or steering so patients would still be 
required to have a colonoscopy if any pathology is found.  
 
Colonoscopy remains the superior test in its ability to detect pathology, obtain 
colonic tissue samples and allow for therapeutic procedures simultaneously. An 
increase in screening colonoscopy uptake has been linked to a reduction in 
colorectal cancer and mortality 41,42. Studies have shown that patients aged 55-
64 who undergo single screening flexible sigmoidoscopy and polypectomy, with 
referral for colonoscopy where high risk features are found, have a reduced 
incidence of colorectal cancer of 23% and mortality of 31% in intention-to-treat 
analyses 43.  
 
1.1.4 Adenoma detection rate  
 
Adenoma detection rate (ADR) is defined as the proportion of screening 
colonoscopies in which at least 1 histologically confirmed adenoma is found. As 
a surrogate marker of thorough mucosal visualisation, it is regarded as the most 
important indicator of quality in colonoscopy and is the most widely accepted 
measure 44–47.  
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Adenoma detection rate is normally utilised as the primary objective of most 
studies that are set on improving quality of colonoscopy. There is a wide 
variation in ADR amongst non-screening colonoscopists but mean ADR has 
been reported as 15.9% 48. For BCSP colonoscopists, the mean ADR is much 
higher at 46.5% 44. This can partially be explained by the increased risk of 
adenomas in patients with a positive faecal occult blood test, but may also 
reflect high quality colonoscopy.  
 
There are other methods of measuring adenomas such as mean adenomas per 
procedure (MAP), mean adenomas per positive procedure (MAP+) and 
advanced adenoma detection rate(AADR). MAP is defined as the total number 
of adenomas detected divided by the number of procedure. There are 
increasing arguments being made for the routine use of MAP and its role in 
measuring quality as ADR essentially only measures the presence of one 
adenoma and therefore the removal of one adenoma 44,49. The identification 
and removal of every adenoma present is important as this determines the 
surveillance interval and reduces the risk of interval colorectal cancer 49.   
 
MAP+ is the total number of adenomas detected divided by the number of 
procedures where one or more adenomas were detected. In the screening 
population, ADR and MAP correlate positively to each other with 53% of 
procedures where adenomas are found demonstrating one adenoma 44. On the 
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other hand, MAP+ correlated less well with ADR. Polyp detection rate (PDR) 
has also been studied and correlates well with ADR in colonic segments 
proximal to the splenic flexure 50. The application of a conversion factor to the 
PDR accurately estimates the ADR 51.  
 
AADR measures adenomas more or equal to 10mm in size with or without the 
presence of villous components or high-grade dysplasia. Advanced adenomas 
occur less frequently but have a higher malignant potential. An American 
observational cohort study of 1933 colonoscopies from 14 colonoscopists 
reported significant variations in ADR and AADR but found no correlation 
between them 52. This may be a result of an increase in small non-advanced 
adenomas that are counted towards ADR, as demonstrated by a German study 
analysing trends in ADR in a screening programme 53. 
 
1.1.5 The relationship between adenoma detection rate, missed lesions 
and interval colorectal cancers 
 
Although colonoscopy is the gold standard investigation, it remains an 
imperfect tool for cancer prevention and can be improved upon. Low ADR is 
implicated as one of the primary reasons for interval colorectal cancers which 
are colorectal cancers that develop after colonoscopy.  Interval colorectal 
cancers are also often called post colonoscopy colorectal cancers in literature.  
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A few population-based studies have shown that up to 7.2% of patients newly 
diagnosed with colorectal cancer underwent a colonoscopy within a few years 
prior to diagnosis 54,55. They defined interval colorectal cancers as patients with 
a diagnosis of cancer 3 years after index colonoscopy 54,55.  A population-based 
study in the Netherlands of 5107 patients discovered that 2.9% of diagnosed 
colorectal cancers were interval colorectal cancers. In this group of patients, 
57.8% were because of missed lesions. Their definition of interval colorectal 
cancers were patients who had a cancer diagnosed 5 years after index 
colonoscopy. Interestingly, they concluded that 86% of interval colorectal 
cancers were preventable as they were due to factors like missed lesions, 
inadequate examination or surveillance. Most the lesions that were missed were 
proximally located, small and had a flat appearance 56. It is clear that lesions 
that go on to become cancers in a select group of patients are still being missed.  
Missed lesions are polyps or adenomas that are missed during index 
colonoscopy. There are many reasons for missed lesions which include; 
suboptimal technique; shorter withdrawal time; inadequate bowel preparation; 
presence of flat, depressed or subtle lesions; and the inability to visualise the 
proximal side of haustral folds, flexures (blind spots), rectal valves and 
ileocaecal valve 57–59. It has been estimated that 10% of the colonic surface 
remains to be observed under the standard forward-viewing colonoscope even 
with good bowel preparation 60.  
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Adenoma miss rate is calculated by dividing the total number of adenomas 
found on repeat examination by the total number of adenomas found on initial 
and repeat examination. The miss rate for adenomas have been quoted at up to 
24% 59,61. Small adenomas (<10mm in size) have a significantly higher miss rate 
compared to larger adenomas (>10mm) 59. As adenoma miss rate can be 
difficult to calculate as it requires tandem colonoscopy, most studies use the 
ADR rate as a measure of quality in identifying and removing adenomas. 
Missed lesions or a low ADR is implicated as one of the primary reasons for 
interval colorectal cancers.   
 
Two large studies have illustrated the relationship between a low ADR and high 
interval colorectal cancer rate.  A large Polish study evaluated 1866 
colonoscopists and 45,026 colorectal screening patients and identified 42 
interval colorectal cancers. A low ADR was associated with a greater risk of 
interval colorectal cancer (P = 0.008.). The hazard ratio for interval colorectal 
cancers where the colonoscopist had an ADR of less than 20% was ten times 
that of colonoscopists with an ADR of greater than 20%. This provided a clear 
correlation that ADR was an independent predictor of the risk of interval 
colorectal cancer after screening colonoscopy 47. In contrast, Corley et al 
studied 300,000 colonoscopies performed by 136 colonoscopists for screening, 
surveillance or diagnostic purposes and found an inverse relationship between 
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ADR and the risk of interval colorectal cancer, advanced-stage interval 
colorectal cancer and fatal interval colorectal cancers. ADR ranged from 7.4 to 
52.5% and was inversely related to the risk of developing interval colorectal 
cancer. A 1% increase in ADR was associated with a 3% reduction in the risk of 
interval colorectal cancer and a 5% reduction in risk of a fatal interval 
colorectal cancer 62. Thus, if we increase ADR, there is evidence that the risk of 
interval colorectal cancers can be reduced substantially.  
 
1.1.6 Factors influencing ADR  
 
Despite a variation in ADR, there has been an improving trend in the United 
Kingdom over recent years 63–65. The reasons for these are explored in further 
detail.  
 
1.1.6.1 Endoscopy training programmes  
 
The Joint Advisory Group on Gastrointestinal Endoscopy (JAG) was established 
in 1994 with the initial aim of supporting doctors in training. It now oversees 
quality assurance for endoscopy units and services, sets standards for 
competencies, regulates accreditation of units and individual endoscopists and 
is heavily involved in education and training. The National Endoscopy Training 
Programme was created by JAG and has resulted in an overall improvement in 
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endoscopy training in the UK.  The JAG Endoscopy Training System (JETS) is 
an e-portfolio system that enables training progress and competencies to be 
monitored in addition to providing a platform for set training standards. Table 1 
illustrates the criteria required for full certification in colonoscopy by JAG. 
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Table 1 - JAG Criteria for full certification for colonoscopy 66  
* DOPyS are Direct Observational Procedure assessment forms specifically created to 
assess polypectomy 
Criteria for full criteria  Requirements 
Colon provisional certification Granted 
Caecal intubation rate ≥ 90% 
Unassisted (physically) ≥ 90% 
Formative DOPyS*(level 2) ≥ 4 
Polypectomy techniques assessed by DOPyS (level 2) – 
Stalked polyps 
≥ 1 
Polypectomy techniques assessed by DOPyS (level 2) – 
Small sessile lesions/ EMR 
≥ 1 
Formative DOPyS scores ≥ 90% “3”s and “4”s 
Polyp detection and removal  ≥ 10% 
Sedation rate for patients aged < 70 < 5mg midazolam 
Sedation rate for patients aged > 70 < 2.5mg midazolam 
Analgesia rate for patients aged < 70 < 50mg pethidine, < 
100µg fentanyl 
Analgesia rate for patients aged > 70 < 25mg pethidine, < 50µg 
fentanyl 
Serious complication rate < 0.5%  
Number of procedures completed since award of 
provisional certification 
≥ 100 
Recommended lifetime procedure count ≥ 300 
Procedures in previous 3 months ≥ 25 
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A study investigating adenoma miss rates in patients undergoing tandem 
colonoscopy by a trainee followed immediately by an experienced 
colonoscopist showed that adenoma miss rates improved with experience of 
the trainee 67. Along with better training because of JAG, there is also an 
increased awareness in quality improvement measures that can be utilised to 
improve adenoma detection rate. This includes measures like using better 
bowel preparation, longer withdrawal times, using hyoscine-n- butylbromide, 
performing rectal retroflexion and utilising dynamic patient position changes.  
 
1.1.6.2 National screening programmes 
 
Population screening programmes result in earlier detection of CRC’s at a more 
treatable stage by detecting and removing adenomas that may become 
malignant over time thus reducing CRC mortality 68. The introduction of the 
National Health Service Bowel Cancer Screening Programme (NHS BCSP) in 
2006 which utilises faecal occult blood population screening has also resulted 
in an increase in quality of colonoscopy. The NHS BCSP aims to improve 
outcomes from colorectal cancer through earlier detection but has 
inadvertently contributed towards adenoma detection and removal 69.   
 
All BCSP colonoscopists must undergo strict accreditation criteria via the 
Screening Assessor Accreditation System which is a web-based application 
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process maintained by JAG. This includes achieving caecal intubation rates of 
more than 90% and ADR of more than 20% in a total of at least 1000 
procedures within a 12-month period prior to being accredited as BCSP 
colonoscopists. Completion of accreditation examination at an independent 
unit is then undertaken which consists of multiple choice question examination 
and performance of two colonoscopies observed by two independent and 
trained examiners using objective directly observed colonoscopic procedural 
skills assessment criteria.  Following on from this, they are subjected to a 
rigorous ongoing audit of performance which include carrying out a minimum 
of 150 screening colonoscopies annually, having a complication rate below the 
national average, maintaining caecal intubation rate of more than 90% and 
ADR of more than 35% in patients within the BCSP programme 70.  
 
ADR in the NHS BCSP has been reported at 29% in women and 43% in men 71. 
ADR is comparatively higher in BCSP colonoscopist by 30% compared to non-
BCSP colonoscopists 44. This may be explained by an increased risk of 
adenomas in NHS BCSP patients who attend because of positive faecal occult 
blood tests but may also reflect higher quality colonoscopy. The quality of BCSP 
colonoscopy has been reported widely 44.  
 
The English Bowel Scope Screening (BSS) programme began in 2013 and invites 
adults aged 55 and above for a one off-flexible sigmoidoscopy. The aim of the 
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BSS programme is to reduce CRC development via the adenoma-carcinoma 
sequence through the detection and removal of adenomas from the left side of 
the colon. At present, ADR is not as high as expected in BSS patients compared 
to the NHS Bowel Cancer Screening Programme with the national ADR 
reported at 9.2%72. However, a large UK study has shown that offering one-off 
flexible sigmoidoscopy screening to adults aged 55-64 years reduces CRC 
incidence by 23% and mortality by 31% 43.  
 
1.1.6.3 Quality in colonoscopy 
 
A large study of UK colonoscopy practice carried out in 2004 audited the 
performance of 68 endoscopy units in the UK. This reported inadequate 
colonoscopy completion rates of 56.9% and polyp detection rates of 22.5%. In 
addition, only 17% of colonoscopists had received supervised training for their 
first 100 colonoscopies and only 39.3% of colonoscopists had attended a 
training course 64. These stimulated significant improvements to colonoscopy 
training and toughened the case for national bowel cancer screening 
programmes as previously discussed. This combination has resulted in 
benchmarking of standards and an increased awareness of the need for good 
quality colonoscopy. High quality colonoscopy is crucial to ensure maximal 
pathology detection and has been shown to reduce the incidence of colorectal 
cancer 47. The aim in a high-quality colonoscopy is perform a complete 
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procedure in which the caecum is reached, the mucosa inspected thoroughly, 
patient comfort maintained and any pathology adequately diagnosed and dealt 
with 73. In addition, a report of the procedure should be completed with photo-
documentation of specific landmarks and abnormalities 46.  
 
Multiple factors are responsible for the variation in ADR which include; 
suboptimal technique; shorter withdrawal time; inadequate bowel preparation; 
presence of flat, depressed or subtle lesions; and the inability to visualise the 
proximal side of haustral folds, flexures (blind spots), rectal valves and 
ileocaecal valve 57–59. It has been estimated that 10% of the colonic surface 
remains to be observed under the standard forward-viewing colonoscope even 
with good bowel preparation 60. Therefore, it is unsurprising that other key 
quality indicators have been proposed for colonoscopy include bowel 
preparation scores, caecal intubation rate, withdrawal time, completeness of 
polyp removal and patient safety and satisfaction 58. 
 
Firstly, patients with good bowel preparation scores have a higher ADR. A 
systematic review and meta-analysis of 11 studies by Clark et al illustrated that 
ADR was significantly higher in patients with adequate versus inadequate 
bowel preparation with odds ratio of1.30 (1.10-1.42) and 1.30 (1.02-1.67). There 
was no significance in patients with intermediate quality versus high quality 
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bowel preparation which may be because it is often possible to remove small 
amounts of soft faecal material with saline flushes during colonoscopy 74. 
During colonoscopy, the colon is examined predominantly in the withdrawal 
phase which has been the subject of scrutiny for many studies trying to 
establish a link between the withdrawal phase and ADR.  A study of 31,088 NHS 
BCSP colonoscopies found that a longer withdrawal time of more or equal to 11 
minutes compared to less than 7 minutes improved mean ADR from 42.5% to 
47.1% 75. This is echoed by another large study of 10,955 procedure in the United 
States which found that colonoscopy withdrawal time of 7 minutes was 
associated with median PDR 76. Shorter withdrawal times of less than 6 minutes 
are associated with lower ADR and an increased risk of interval colorectal 
cancer 63,77.  
 
In addition, the positioning of patients during colonoscopy and the anatomy of 
the colon means that not all segments of the colon are distended during the 
procedure. The use of dynamic position change has been shown allow luminal 
gas to rise and fluid to drain away from the segment of interest using gravity. A 
study by East et al demonstrated that carrying out specific and purposeful 
position changes for different segments of the colon correlated with 
significantly higher ADR 78.  
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Bowel spasms and the presence of folds can complicate thorough inspection of 
colonic mucosa during the withdrawal phase. The administration of 
antispasmodics such as hyoscine-n-butylbromide have been found to improve 
ADR in small studies 79,80. Various endoscopic devices have been invented to 
improve adenoma detection rate. This will be discussed in further detail in the 
next section.  
 
1.2 Devices in colonoscopy  
 
1.2.1 Introduction  
 
Optical imaging innovations and technological developments in the field of 
colonoscopy have attempted to increase adenoma detection rates with the 
introduction of high-definition endoscopes, electronic chromo-endoscopy 
(including narrow band imaging), wide angle colonoscopy and retrograde 
viewing devices 81,82. However, lesions located on the proximal sides of colonic 
folds can still be missed during standard conventional colonoscopy 83. Although 
these views may be improved with dynamic patient position changing and 
routine retroflexion, these manoeuvres may not be effective, particularly in 
narrower colonic segments, even with the use of a paediatric colonoscope or 
gastroscope 78,84. Transparent caps and hoods that attach to the tip of the scope 
have been created to hold down folds and improve visualisation in the forward 
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view. However, they can make the tip of the scope more rigid and longer which 
may impair insertion in an angulated sigmoid colon 85,86.  
 
1.2.2 Imaging modalities  
 
1.2.2.1 High definition colonoscopy  
 
High definition colonoscopy is the use of a high definition monitor resulting in 
more images per second being shown with a higher resolution compared to 
standard colonoscopy thus improving image quality and potentially identifying 
more pathology.  
 
Early studies did not report a significant difference in ADR when comparing 
high definition colonoscopy with standard colonoscopy 87–92. The earliest 
positive result was a cohort study where the total number of nonflat, >6mm 
adenomas was higher in the high definition group compared to standard 
colonoscopy87. A retrospective study of 2430 patients reported a significant 
increase of 4.5% in ADR in patients with high definition colonoscopy with an 
up to 3% increase found in adenomas less than 5mm in size. However, 
confounding factors such as withdrawal time and quality of bowel preparation 
were not standardised 93.  
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Two recent studies have reported a significant increase in ADR (8.2% p=0.02, 
12.6% p=0.007) with high definition colonoscopy 94,95.  However, these were 
retrospective cohort studies. A meta-analysis of 4422 patients described 
marginal differences between high definition colonoscopy and standard 
colonoscopy for the detection of adenomas with an incremental yield of 3.5% 
(95% CI 0.9%-6.1%) with a number needed to treat of 28 96.  
 
In conclusion, high definition colonoscopy appears to improve ADR. However, 
prospective studies are required to further confirm this.   
 
1.2.2.2 Conventional chromo-endoscopy 
 
Conventional chromo-endoscopy utilises contrast dyes that allow for 
enhancement of the colonic mucosa, thus improving visualisation and 
highlighting surface contours (Figure 2b). In conventional pan colonic chromo-
endoscopy, dye in the form of indigo carmine or methylene blue is sprayed with 
a catheter or is applied directly through the working channel of the endoscope 
in a segmental fashion onto the entire colorectal mucosa.  
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Figure 2: (a) High definition endoscopy and (b) conventional chromo-
endoscopy, (c) high definition endoscopy and (d) narrow band imaging, (e) 
high definition endoscopy and (f) autofluorescence imaging97 
 
A Cochrane systematic review analysed seven RCTs with a total of 2727 
participants and assessed the role of conventional chromo-endoscopy 
compared to standard colonoscopy in polyp detection and found that chromo-
endoscopy generated more participants with at least one neoplastic lesion (OR 
1.53, 95% CI 1.31-1.79) and at least one diminutive neoplastic lesion (OR 1.51, 95% 
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CI 1.19 to 1.92)98. They concluded that conventional chromo-endoscopy 
improved the detection rate of small polyps by 90%98.  Thus, chromo-
endoscopy may have a role in improving ADR.  
 
1.2.2.3 Virtual chromo-endoscopy  
 
Virtual chromo-endoscopy utilises a narrow spectrum of wavelengths with a 
decreased penetration depth to enhance visualisation of the colon mucosa. 
These narrow wavelengths increase the vascular contrast of the mucosa and 
allows for improved visualisation of the colonic mucosal surface. Different 
manufacturers have developed their own systems of virtual chromo-endoscopy 
and the use of such modalities has been proposed for characterisation of 
colonic lesions99. 
 
1.2.2.3.1 Narrow Band Imaging (NBI) 
 
Narrow band imaging uses narrow band filters placed behind the light source 
that eliminate red light and increase the exposure of blue and green light. Blue 
light (415nm) enhances the visualisation of superficial mucosal capillaries while 
green light (540nm) increases the visibility of submucosal and mucosal vessels 
(Figure 2d).  
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A Cochrane review of 11 RCT’s and 3673 patients in 2012 found no evidence to 
suggest that NBI was significantly better than standard colonoscopy at 
improving detection rates in average risk populations 100. Six successive RCT’s 
have reflected this and shown no significant increase in ADR with NBI 101–106. In 
contrast, a single centre RCT found higher adenoma miss rates in standard 
colonoscopy compared to high definition colonoscopy utilising NBI (49% 
versus 27%, p-0.036)107.  The authors argued that because two different 
colonoscopes were used in tandem compared to the other previously reported 
studies – standard colonoscopy followed by another colonoscope with better 
definition and high contrast, their study was more representative of a true miss 
rate.  
 
There is evidence that NBI may be of benefit in high risk population groups 
such as Lynch Syndrome,  and hyperplastic polyposis syndrome in ADR 108,109 . 
In Lynch syndrome, the use of NBI in the proximal colon for surveillance 
colonoscopies improved ADR by 15%108 whereas NBI has been reported to 
significant reduce polyp miss rate by 26% in hyperplastic polyposis syndromes 
109.  
 
Current evidence has not demonstrated that NBI significantly improves ADR in 
normal risk individuals. However, NBI may be of benefit in high risk 
individuals.  
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1.2.2.3.2 Fuji Intelligent Colour Enhancement (FICE) 
 
Fuji Intelligent Colour Enhancement is a computed spectral estimation 
technology system that enhances the visibility of mucosal and vascular details 
by narrowing the bandwidth of light. FICE offers the endoscopist the choice of 
different wavelengths for optimal views. 
 
Three tandem RCTs and one none tandem RCT have shown no significant 
benefit of FICE over standard colonoscopy or NBI 110–113 in improving ADR. 
However, in the tandem RCT by Chung et al, inadequate bowel preparation in 
at least 50% of may have impacted on ADR110. Yoshida et al also reported that 
poor visibility was noted with FICE for blood visibility, which may affect 
detection of more vasculated adenomatous lesions112.  There is no strong 
evidence that FICE improves ADR. 
 
1.2.2.3.3 Autofluorescence Imaging (AFI) 
 
Autofluorescence imaging produces real-time pseudo-colour images by a 
rotating filter that produces short wavelength light. Tissue exposure to this 
light leads to excitation of endogenous substances and subsequent emission of 
fluorescent light (Figure 2f).  
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A tandem prospective study of 88 patients found an ADR rise of 8% with AFI 
which increased to 30.3% when performed by less experience endoscopists114. 
However, this study only looked at the rectum and sigmoid area. There are no 
large RCTs available yet for this modality. A recent meta-analysis of six studies 
with 1199 colonoscopies found no significant differences in ADR or PDR in AFI 
compared to WLE but reported that AFI did significantly decrease AMR (OR 
0.62; 95 %CI 0.44 – 0.86) and PMR (OR 0.64; 95 %CI 0.48 – 0.85) 115.   
 
More evidence is required from RCTs to determine the role of AFI in improving 
ADR.  
 
1.2.2.3.4 i-SCAN  
 
i-SCAN is another virtual chromo-endoscopy system designed to enhance 
surface and vascular pattern to improve optical diagnostic performance. It has 
three modes of image enhancement which are surface enhancement, contrast 
enhancement and tone enhancement. 
 
Two randomised controlled trials reported conflicting ADR results. One study 
showed that i-SCAN improved ADR by up to 25% compared to standard 
colonoscopy 116. However, this study compared high definition colonoscopy and 
i-SCANTM with standard definition colonoscopy. High definition colonoscopy 
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has been shown to be more sensitive in detecting small flat polyps and 
therefore this may not be a true representation of i-SCAN 87,90. Only one study 
compared standard colonoscopy with standard colonoscopy and i-SCAN which 
is a better representation of the effectiveness of using i-SCAN in the average-
risk population. This study concluded that there was no improvement in ADR 
but that i-SCAN played a role in real-time histology prediction of polyps 117.  
 
The largest cohort study of 1936 patients reported higher ADR with i-SCAN 
including higher advanced adenoma detection rates 118. However, the role of i-
SCAN in improving ADR has not yet been proven conclusively and larger RCTs 
are required.  
 
1.2.2.3.5 Endoscopic Trimodal Imaging (ETMI) 
 
Endoscopic trimodal imaging (ETMI) combines the use of high definition 
endoscopy, autofluorescence imaging and narrow band imaging during 
colonoscopy.  
 
The use of ETMI in tandem colonoscopy RCTs has not been found to 
significantly reduce adenoma miss rates or improve ADR119–121. One study 
utilised non-academic endoscopists whilst the other two RCTs were conducted 
at expert centres. Two of these RCT’s also recruited high risk patients with a 
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history of previous adenomas, cancer or a positive family history of cancer. 
Therefore, ETMI has not yet been demonstrated to improve ADR. 
 
1.2.3 Devices to attach to scope  
 
1.2.3.1 Cap-assisted colonoscopy 
 
Cap-assisted colonoscopy is the use of transparent caps that attach to the distal 
tip of the colonoscope to flatten colonic folds to improve mucosal visualisation 
proximally (Figure 3).  
 
 
Figure 3: (a) A small cap to attach to the tip of the colonoscope, (b) view of 
mucosal lumen with cap-assisted colonoscopy which improves visualisation 
behind folds and flexures 97 
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There have been mixed results in RCTs evaluating the diagnostic yield of cap-
assisted colonoscopy. Initial studies which often included a small sample of 
endoscopists and had a limited sample size showed no improvement in ADR 
with cap-assisted colonoscopy 86,122,123.Some studies utilised polyp detection rate 
instead of ADR as their primary outcome 124. A Cochrane review also concluded 
that cap –assisted colonoscopy increased polyp detection rate but there was not 
enough evidence to suggest it increased ADR as well125.  A further systematic 
review concluded that there was an improvement in right sided adenomas with 
cap-assisted colonoscopy126.   
 
Other studies have shown equivocal results but they did show that cap-assisted 
colonoscopy improved patient comfort compared to standard 
colonoscopy85,127,128. The CAP study utilised a two-centre, multi-endoscopist, 
randomised controlled trial approach to determine the role of cap-assisted 
colonoscopy in adenoma detection129. There was no significant difference found 
with ADR in both groups. Cap-assisted colonoscopy seemed to be of benefit for 
some endoscopists who experienced an increase in ADR by 20% whereas in 
others, there was a 15% decrease. This was not related to endoscopist 
experience129.   
 
In conclusion, cap-assisted colonoscopy has not yet been demonstrated to 
convincingly improve ADR.    
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1.2.3.2 EndoRings 
 
EndoRings is a silicone endoscopic add-on device that consists of a short tube-
like core with several layers of flexible circular rings. It is attached to the tip of 
the scope and during scope withdrawal; the rings centre the scope and 
straighten colonic folds, thus enhancing mucosal views (Figure 4).  
 
 
Figure 4: EndoRings attachment on a colonoscope 130 
 
One multicentre, randomised, tandem study has been completed comparing 
the use of EndoRings with standard colonoscopy and demonstrated a lower 
adenoma miss rate with EndoRings colonoscopy. There was no significant 
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difference in caecal intubation or withdrawal times although total procedure 
time was longer in EndoRings colonoscopy group due to removal of more 
polyps131. 
 
The initial study suggests benefits from EndoRings. However, further RCTs are 
required to validate this.  
 
1.2.3.3 Third Eye Panoramic  
 
The Third Eye Panoramic device is a clip that is attached to the tip of a 
standard colonoscope to provide two additional video cameras. This results in 
three images which provide a panoramic view and reveals parts of the lumen 
that may otherwise be hidden with standard colonoscopy (Figure 5). The Third 
Eye Panoramic is a device that can be cleaned, disinfected and used multiple 
times prior to disposal.  
 
Figure 5: Third Eye Panoramic device132 
  
 
55 
A small prospective observational study of 33 patients illustrated that the Third 
Eye Panoramic device enhanced colonic views with a caecal intubation rate of 
100% and an overall adenoma detection rate of 44%133.  
 
This seems to be a promising device but RCT’s are required to explore the role 
of this device in colonoscopy.  
 
1.2.3.4 Endocuff and Endocuff Vision 
 
Endocuff is a device made up of polypropylene core and elastomer projections 
that work to enhance mucosal visualisation of the colon. Endocuff Vision is a 
newer version of the Endocuff. This will be discussed in further detail in the 
next section. 
 
1.2.4 Different types of colonoscopes  
 
1.2.4.1 Full Spectrum Endoscopy (FUSE) 
 
Full spectrum endoscopy utilises a colonoscope that allows for a high 
resolution 330 degrees “full spectrum” view of the colonic lumen. It consists of a 
main control unit and a video colonoscope with three imagers and LED groups 
located at front and both sides of the flexible tip. The video images transmitted 
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from the three cameras on the left side, front and right side of the colonoscope 
are displayed on three continuous monitors. The addition of the two side 
cameras provides a more comprehensive view of colonic mucosa and visualises 
blind spots more easily (Figure 6). 
 
 
Figure 6: Full spectrum endoscopy compared to standard colonoscopy 134 
 
An initial prospective single centre pilot cohort feasibility study showed that 
FUSE was feasible, usable and safe 135. Following on from this, a multicentre, 
randomised, tandem colonoscopy trial illustrated that the adenoma miss rate 
was significantly lower in patients in the FUSE group (7% versus 41%, 
p<0.0001)136. This result has been mirrored by a Greek tandem study that 
reported lower miss rates by 23% with FUSE.  It is argued that the use of FUSE 
could lead to an absolute reduction of 145 USD dollars per patient due to a 
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significantly higher sensitivity associated with FUSE 137. However, a recent 
Italian RCT reported no statistifically significant difference in ADR and AADR 
between FUSE and standard colonoscopy in screening programme patients 138.  
 
Therefore, there is inconclusive evidence for the use of FUSE in reducing 
adenoma miss rates. In addition, more studies are required to determine the 
learning curve of looking at three monitors at the same time and the efficacy of 
FUSE in day to day endoscopy practice.   
 
1.2.4.2 Third Eye Retroscope (TER) 
 
Third Eye Retroscope was invented to enhance the visualization of proximal 
colonic folds. It is a device that consists of a video processor, a single-use 
polarizing filter cap for colonoscope light source and a 3.5mm flexible single-
use catheter with a camera and diode light source at the tip. The TER is 
retroflexed at 180 degrees after being inserted through the working channel of 
the colonoscope and provides a 135-degree retrograde view of the colon (Figure 
7).  
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Figure 7: Third Eye Retroscope 132 
 
The TERRACE study which was the only randomised back-to-back study of TER 
found a net additional detection rate of 30% for polyps and 23% for adenomas 
139. The disadvantages of TER are that it needs to be removed from the working 
channel if an accessory device is required. The insertion of TER reduces the 
suctioning capacity by 50% and it is also expensive as a single use, disposable 
device. More RCTs are required to assess the role of TER in ADR improvement.   
 
1.2.4.3 NaviAid G-EYE Balloon Colonoscope 
 
The NaviAid G-EYE colonoscope is made up of a standard colonoscope with a 
permanently integrated, reusable balloon at the distal end of the colonoscope. 
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It allows for the colonoscope to be withdrawn with the balloon partially 
inflated, thus allowing for straightening of haustral folds and improving 
mucosal views. In addition, the balloon can be inflated to help anchor and 
stabilise the colonoscope when required (Figure 8).  
 
 
Figure 8: NaviAid G-EYE colonoscopy 140 
 
A prospective cohort study of 50 patients identified an ADR of 45% with no 
major complications141. A recent tandem randomised controlled trial found that 
the adenoma miss rate of NaviAid G-EYE colonoscopy was significantly lower 
7.5% vs 44.7%, P=0.0002) compared to standard colonoscopy142. This was a 
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relatively small trial of 106 patients and the same colonoscopist performed both 
tandem procedures and was not blinded to the technology used.  
 
In conclusion, large RCT’s are required to further investigate the role of 
NaviAid G-EYE Balloon Colonoscope in ADR improvement.  
 
1.2.4.4 Aer-O-Scope colonoscope 
 
The Aer-O-Scope consists of a disposable scanner which is the colonoscope 
component and a work station. The disposable scanner is made up of a soft 
multi-lumen tube with a unique pneumatic self-propulsion system that utilises 
balloons and low-pressure carbon dioxide gas. This system maximises the views 
of the entire colonic mucosa, including behind haustral folds. The lens head 
enables 360 degrees panoramic, omni-directional visualisation on a single 
screen (Figure 9).  
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Figure 9: Aer-O-Scope 143 
 
A pilot study of 12 patients found a promising caecal intubation rate of 83% 
with no complications observed144 but there are no RCTs comparing the use of 
Aer-O-Scope against standard colonoscopy. Thus, larger studies are required to 
assess the safety and accessibility of Aer-O-Scope before considering its role in 
ADR improvement. 
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1.2.4.5 Extra wide angle view colonoscopy (EWAVE) 
 
The extra wide angle view colonoscope has a 147-235 degree angle lateral and 
backward view lens and a standard 140 degree angle forward view lens and is 
able to combine views from both lenses to display a single image (Figure 10).  
 
 
Figure 10 : Extra Wide Angle View Colonoscope145 
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 The only published study so far is a small study of 47 patients where 57.1% of 
polyps were detected with the lateral-backward view. This study concluded that 
E-WAVE was safe and feasible with potential to improve ADR146.  
 
More studies are required to determine the role of E-WAVE in colonoscopy.  
 
1.2.5 Others 
 
1.2.5.1 Water immersion and water exchange colonoscopy  
 
Water immersion colonoscopy is the infusion of water during the insertion of 
the colonoscope with air insufflation. This method allows water to flow in the 
direction of the lumen which assists in locating the correct direction for 
intubation. Water immersion has been shown to reduce pain scores, reduce the 
need for sedation and improve tolerability of the procedure (102). Early studies 
reported no differences in ADR when comparing water immersion with air 
insufflated colonoscopy 147. 
 
Water exchange colonoscopy is the infusion of water during the insertion of the 
colonoscope without air insufflation.  It is a technique where water containing 
faeces is removed and exchanged for clean water in the absence of air 
insufflation. Early RCTs reported no improvement in ADR 148,149.  
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A Cochrane review of 16 RCTS and 2933 patients found the main benefit of 
water immersion and water exchange colonoscopy to be reduction in pain 
scores150. There was also a small improvement in ADR (RR 1.16, 95%CI 1.04 to 
1.30, P=0.007)150. A recent RCT of 1200 patients reported that water exchange 
colonoscopy achieved higher ADR (adenomas < 10mm) in the right colon of 5% 
in compared to water immersion and 4.7% compared to air insufflation 
colonoscopy151.  The results are promising but further evidence for the benefit of 
water aided colonoscopy from RCTs is required.  
 
1.3 The birth of Endocuff and Endocuff Vision 
 
To understand how the Endocuff was invented, it is important to consider the 
background of its inventors. Professor Anthony Axon is a retired Consultant 
Gastroenterologist who qualified in medicine with Distinction from Bart’s and 
The London University in 1965. He was appointed as a Consultant 
Gastroenterologist at The General Infirmary at Leeds in 1975 and was awarded 
the honorary title of Professor of Gastroenterology by the University of Leeds in 
1995. He retired from clinical practice in 2012 but is still currently active in the 
medico-legal field, medical research and medical education. He has three 
children – Patrick who trained in surgery, Anthony who became a barrister and 
Antonia who qualified as a General Practitioner. The Endocuff project became a 
family affair but Patrick Axon has become the main driving force behind the 
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device. In his spare time, he works as a Consultant Otologist, Hearing Implant 
and Skull Base Surgeon who works at Addenbrooke’s Hospital within the 
Cambridge University Hospitals NHS Foundation Trust. 
 
The notion of Endocuff came about as Professor Axon was devising devices that 
would allow for more stability in the caecum during colonoscopy. Together 
with input from the rest of the family they formed ARC Medical Design Limited 
in 2008 and sourced the help of a design company – Design Edge to form the 
first prototype of the Endocuff. The main objective of the Endocuff at that point 
was for its finger-like projections to grapple onto the colonic folds thus 
propelling the colonoscope further towards the caecum. However, they quickly 
discovered during experimental stages that the Endocuff seemed be more of 
use in holding back colonic folds during withdrawal of the colonoscope.   
 
The Endocuff is a new disposable device that is made up of a polypropylene 
core and thermoplastic elastomer ‘finger like’ projections. It was first CE 
marked in August 2011. The first version of Endocuff comprised backwards 
pointing flexible ‘finger like’ 12mm projections at intervals around the device 
circumference (Figure 11). It is mounted at the tip of the scope and held on by 
friction with a minimum pull-off force of 10 Newton’s. It anchors the scope tip 
against the bowel wall to provide a stable platform of access. The soft, elastic 
projections are pushed back and recoil towards the scope shaft during insertion 
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but evert during withdrawal to hold colon folds away from the field of view 
allowing for excellent visualisation of the colonic lumen. The distal end of the 
Endocuff does not extend beyond the tip of the colonoscope and therefore does 
not get in the way of the suction, flushing or working channels. Endocuff is 
available in four different sizes (length of 23.8mm x diameters of 
16.1/16.7/17.2/18.5mm with the finger like projections folded back and 
32.6/33.1/33.6/34.8mm with finger like projections opened out) and therefore 
compatible with most colonoscopes.  
 
 
Figure 11: Endocuff (personal photograph by author) 
 
The use of Endocuff is contraindicated in patients with known colonic 
strictures or active inflammatory disorders such as acute infective colitis, 
colonic Crohn’s disease, ulcerative colitis and acute diverticulitis. Endocuff has 
won multiple industry awards namely the ‘Industrial Product Design of the 
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Year category of the Plastics Industry Awards 2013’ that is dedicated to 
rewarding innovation and exceptional performance to the best designers within 
the polymer field. It has also won the’ Red Dot Award’ in 2012 and a Silver 
Award in the ‘A Designs Awards 2013’.   
 
There have been a few studies looking at the role of Endocuff during 
colonoscopy with promising results. The first study performed was a case series 
of 12 patients, which looked at complex sigmoid polyp resection and scar 
assessment in the sigmoid colon. A complete colonoscopy was not performed.  
The authors concluded that Endocuff-assisted colonoscopy (EAC) was a safe 
and easily used device. However, they reported minor mucosal ‘scratches’ 
observed in 25% of patients 152. Following on from this in 2013, German 
researches carried out a study of 50 EAC procedures with caecal intubation rate 
of 98%, ileal intubation rate of 76% and ADR of 34%. In 30% of patients, small, 
superficial, “scratch-like” mucosal lesions were observed, especially in the 
ileocaecal region 153.   
 
In the United States, a case series of 93 EAC and 143 standard colonoscopy (SC) 
procedures was reported with EAC resulting in a higher PDR (78.5% vs 57.3%, 
p<0.001, higher ADR (44.1% vs 27.3% p=0.01), flat polyp detection rate (23.8% vs 
12.3% p=0.04) and sessile serrated adenoma detection rate (10.8% vs 4.2%, 
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p=0.06). The mean number of polyps per procedure was higher in the Endocuff 
group (2.99 vs 1.60, p=<0.001). Polyp detection was not improved with the use 
of the Endocuff in the average risk screening population 154.  Subsequently, a 
Swiss pilot study of 104 screening colonoscopies utilising Endocuff 
demonstrated an ADR of 47% with no adverse events noted 155.  
 
Initially, the most promising results were from two large multicentre trials from 
Germany and the United States. In Germany, a four-centre prospective trial 
randomised 500 patients to EAC or SC with the primary outcome measure 
being ADR. There was an increase from 21% to 35% in ADR (p=0.0001) with an 
absolute increase of 14% and a relative improvement of 74%. The total number 
of adenomas detected increased from 88 to 144 with a relative improvement of 
64%. There was no difference in procedural and withdrawal times and caecal 
and ileal intubation rates were unchanged. Interestingly, there were no reports 
of mucosal lacerations or adverse events in this larger trial 156. 
 
In the United States, a multicentre study retrospectively compared 165 patients 
with EAC and 153 patients with SC.  The average number of polyps detected per 
patient in the Endocuff group was 1.31 vs. 0.82 (p=<0.001) and the average 
number of adenomas 0.8 vs 0.38 (p=<0.001) which is an increase of 110%. The 
ADR was also higher amongst patients where the Endocuff was used compared 
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with standard colonoscopy (46.6% vs. 30.0%, p=0.002) a difference of 16.6%, 
which is 55% more than the original ADR. The Endocuff was also significantly 
superior in right sided adenoma detection (32.1% vs 18.3%; p=0.004). These 
results suggest that EAC may result in higher overall ADR and be more effective 
in detecting right sided adenomas by enabling better inspection of proximal 
colonic folds 157.  
 
An Italian single centre RCT enrolled 288 patients and reported that Endocuff-
assisted colonoscopy increased ADR by 3.3% (p<0.01). In addition, they also 
described mucosal erosions in 2.5% of patients with 1 patient requiring mucosal 
adrenaline injections 158.  
 
The largest multicentre study to date is a recent prospective Dutch study that 
compared the use of Endocuff-assisted colonoscopy with standard colonoscopy 
in 1063 procedures. Interestingly, there was no difference in ADR found 
between both groups (p=0.92). There was a much higher ADR in the control 
group for this study compared to the previous studies from Germany and 
America which may account for this in part. However, MAP was found to be 
higher in the EAC group. In addition, detection of diminutive adenomas 
(<6mm) and flat adenomas was significantly higher in the EAC group. Caecal 
intubation rates were similar in both groups but caecal intubation time (7 vs 8.3 
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minutes, p=0.25) and withdrawal time (median 7 vs 8 minutes, p=0.02) was 
significantly shorter in the EAC group 159. Therefore, it seems that Endocuff may 
still have a role to play in improving colonoscopy quality.  
 
Despite the promising results of Endocuff in improving ADR, the Axon family 
felt that they could improve the Endocuff and aimed to create a new generation 
of the device that would prevent the small, superficial, “scratch-like” mucosal 
lesions that were associated with the earlier studies. This gave birth to the 
Endocuff Vision that consists of a single row of 15mm projections that gently 
evert and flatten folds even in the ascending colon to provide clearer views 
(Figure 12). Endocuff Vision was CE marked in August 2016.  These changes 
deliver yet more tip control without compromising ease of intubation or loop 
management. Each arm is at least 3mm longer than the original Endocuff. In 
addition, it was felt that just having one row of arms instead of two would 
eliminate the risk of trauma to mucosal surfaces as observed with the first 
version.  
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Figure 12: Endocuff Vision (personal photograph by author) 
 
 
 
 
 
 
Figure 13: Endocuff Vision mounted on the tip of a colonoscope (personal 
photograph by author) 
 
St Marks Hospital in London have performed a small pilot study of 3 
experienced colonoscopists in using the new Endocuff Vision attachment in 
their Bowel Cancer Screening Programme by comparing ADR before and after 
using Endocuff Vision. The mean adenoma detection rate rose from 52% to 76% 
  
 
72 
with a caecal intubation rate of over 98% 160. In addition, they compared the 
cumulative ADR of 4 screening colonoscopists before and after the use of 
Endocuff Vision and found that this rose from 48.71% to 65.5%. No adverse 
events have been reported so far in these early small studies 161.   
 
A similar randomised controlled trial that completed recruitment recently is 
the E-CAP (Endocuff-assisted colonoscopy versus standard colonoscopy in the 
faecal occult blood test-based UK Bowel Cancer Screening Programme) trial 
based in Portsmouth. The authors recruited 534 patients and reported no 
significant difference in adenoma detection rate, advanced adenoma detection 
rate or cancer detection rate.  
 
Mean withdrawal time was significantly shorter in Endocuff-assisted 
colonoscopy (16.9 minutes versus 19.5 minutes, p<0.005). However, this study 
was only a single centre study comparing the use of Endocuff-assisted 
colonoscopy versus standard colonoscopy in the screening population 162 .  
 
The ADENOMA (Accuracy of Detection using ENdocuff Optimisation of 
Mucosal Abnormalities) study is the first large multicentre prospective trial 
powered to comparing ADR in Endocuff Vision- assisted colonoscopy versus 
standard colonoscopy in the diagnostic, screening and surveillance population.  
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1.4 Synopsis of the literature to date  
 
Several devices and imaging modalities have been made available. Of these, the 
most promising imaging modalities are high definition colonoscopy and 
conventional chromo-endoscopy. With regards to devices, cap-assisted 
colonoscopy has been studied the most but the results have not yet been 
demonstrated to convincingly improve ADR. Larger randomised control trials 
are still needed to investigate the use of Endocuff Vision, EndoRings, FUSE, 
TER, NaviAid G-EYE and Aer-O-Scope in improving ADR. This study will 
contribute towards determining the efficacy of Endocuff Vision in improving 
ADR.  
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Chapter 2: Aims and Objectives 
 
The intention of this trial was to investigate the use of Endocuff Vision in 
patients attending for a colonoscopy.  
 
Endocuff Vision is designed to improve fold retraction during the withdrawal to 
provide a wider field of view and assist in improving scope tip stabilisation thus 
possibly improving ADR. Endocuff Vision is designed to have a positive effect 
on scope insertion time, caecal or terminal ileal intubation, patient comfort and 
satisfaction.  
 
2.1 Primary objective  
 
The primary objective was to ascertain if there was a difference in adenoma 
detection rate between Endocuff Vision– Assisted colonoscopy (EVAC) and 
standard colonoscopy (SC) patient groups and to quantify this by measuring 
the adenoma detection rate (ADR). 
 
Adenoma detection rate is defined as the proportion of colonoscopies in which 
at least 1 histologically confirmed adenoma is found. It is calculated by taking 
the number of colonoscopies in which there is at least 1 histologically 
confirmed adenoma found divided by the total number of colonoscopies 
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performed in the same time. It is a surrogate marker of mucosal visualisation 
and is regarded as the most important indicator of quality in colonoscopy 163. 
 
2.2 Secondary objectives 
 
The secondary objectives were: 
1. To compare mean adenomas detected per procedure (MAP) between EVAC 
and SC. 
2. To demonstrate non-inferiority of caecal intubation rates and insertion time 
to caecum between EVAC and SC. 
3. To demonstrate non-inferiority in complete withdrawal time in procedures 
where no polyps are detected between EVAC and SC. 
4. To demonstrate non-inferiority of patient satisfaction with EVAC and SC 
groups. 
5. To ascertain the distribution of polyps in the colon in EVAC and SC groups 
by location. 
6. To establish the rate of cuff exchange (that is, how often the cuff has to be 
removed) 
 
In addition, we planned to analyse the data to check for any difference in future 
colonoscopic workload produced by increased ADR in terms of number of 
potential follow up procedures based on British Society of Gastroenterology 
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adenoma surveillance guidelines 164 between the EVAC and SC groups.  
Furthermore, we also compared the ADR of NHS Bowel Cancer Screening 
Programme (BCSP) and non-BCSP colonoscopists, compared the ADR of the 
first 20% of patients scoped by each colonoscopist with the last 20% of patients 
in each arm to identify any changes in ADR and lastly, compared the baseline 
ADR of each colonoscopist prior to trial recruitment with their individual ADR 
in patients where Endocuff Vision was not used. These outcomes were analysed 
on an intention to treat basis.  
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Chapter 3: Methodology 
 
3.1 Study design 
 
This clinical, randomised, multicentre study was conducted in subjects referred 
and scheduled for screening or surveillance colonoscopy via the Bowel Cancer 
Screening Programme (BCSP), diagnostic or surveillance colonoscopy through 
the symptomatic National Health Service (NHS), and compared Endocuff 
Vision-assisted colonoscopy (EVAC) with standard colonoscopy (SC). Patients 
were recruited from 6 participating hospital sites within the Northern Region 
Endoscopy Group and St Mark’s Hospital, London. Initial recruitment began at 
South Tyneside Hospital, North Tees Hospital and St Mark’s Hospital as part of 
an “internal pilot” for 1 month, which allowed for testing of the protocol and 
data collection processes. Any protocol amendments afterwards were 
disseminated to all participating sites. Study data was collected and analysed by 
the principal investigators.  
 
The aim was to recruit 1772 patients. All patients were referred for a 
colonoscopy at each participating site.  All potential participants were given a 
patient information leaflet about the study when their colonoscopy paperwork 
was sent to them, allowing adequate time to read the information leaflet (at 
least 24 hours) before consenting to the study. On attending the endoscopy 
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unit for their procedure, they were approached by a member of the research 
team, and given the opportunity to discuss the study. If they were willing to 
proceed with the study, they completed written consent forms, and baseline 
data was collected. Patients were then randomised to either EVAC group or SC 
group using a computer-generated randomisation tool. Following on from this, 
colonoscopy was performed and intra-procedural data collected by a member 
of the research team and transcribed onto a case report form. Any polyps that 
were detected and removed were followed up at the 21-day review date and 
histological diagnosis recorded post procedure by the research team. All 
colonoscopes were calibrated and serviced as per local guidelines.  
 
Patients remained in the study for 21 days to allow collection of standard post 
colonoscopy complication data through review of medical notes, electronic 
hospital systems or via a phone call to the patient after the 21-day period 
elapsed. Serious Adverse Events (SAEs) were recorded for all patients from the 
day of colonoscopy to 21 days’ post procedure. No additional follow-up visits 
from the patient were required. The timing of routine outpatient appointments 
and results was not affected by the study.  All data was collated and analysed by 
the research team. All adverse events were collected and classified by the 
research team with input from the Data Monitoring Committee.  
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Data collected before colonoscopy: 
1. Patient demographics (age, gender) 
2. Indication for colonoscopy 
3. Past abdominal surgical history 
 
Data collected during colonoscopy procedure: 
1. Polyps detected (total number, plus for each polyp seen; location; size; 
morphology; removed (Yes/No); removal method) 
2. Extent of examination 
3. Insertion time to caecum 
4. Insertion time to terminal ileum (if applicable) 
5. Withdrawal time 
6. Position change  
7. Use of bowel preparation 
8. Use of carbon dioxide insufflation 
9. Patient satisfaction and comfort scores 
10. Immediate complications 
 
Data collected post procedure: 
1. Polyp histology 
2. Complications up to 21 days 
3. Adverse events 
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3.2 Inclusion Criteria 
 
All patients attending for screening, surveillance or diagnostic colonoscopy 
were invited to participate in the study. All patients were aged 18 and over and 
could give informed consent.  
 
3.3 Exclusion Criteria 
 
1. Patients with absolute contraindications to colonoscopy 
2. Patients with established or suspicion of large bowel obstruction or pseudo-
obstruction 
3. Patients with known colon cancer or polyposis syndromes 
4. Patients with known colonic strictures 
5. Patients with a known severe diverticular segment (that was likely to 
impede colonoscope passage) 
6. Patients with active colitis (Ulcerative Colitis, Crohn’s colitis, diverticulitis, 
infective colitis) 
7. Patients lacking capacity to give informed consent 
8. Patients on clopidogrel, warfarin, or other new generation anticoagulants 
who have not stopped this for the procedure 
9. Patients who were attending for a therapeutic procedure or assessment of a 
known lesion 
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10. Pregnancy  
 
3.4 Withdrawal criteria  
 
During colonoscopy, Endocuff Vision was withdrawn in situations where:  
1. There was an acute angulation in a fixed sigmoid colon rendering scope 
insertion not feasible with the Endocuff Vision mounted 
2. There was a new diagnosis of polyposis syndrome 
3. There was a new diagnosis of active colitis (where the colonoscopist is 
concerned regarding the risk of mucosal damage) 
4. There was identification of a new colonic stricture 
5. There was a new cancer diagnosis and progression of the colonoscope with 
the Endocuff Vision attached was not possible.  
 
3.5 Setting/ Participating centres 
 
Seven NHS hospital sites participated and enrolled patients into the trial. Six 
participating sites within the Northern Region Endoscopy Group included one 
tertiary referral centre (North Tees and Hartlepool Hospitals NHS Foundation 
Trust) and five district general hospitals (South Tyneside NHS Foundation 
Trust, , Northumbria Healthcare NHS Foundation Trust, County Durham and 
Darlington NHS Foundation Trust, City Hospitals Sunderland NHS Foundation 
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Trust, South Tees Hospitals NHS Foundation Trust) whilst St Mark’s Hospital 
(London North West Healthcare NHS Trust) was a tertiary referral centre for 
endoscopy. 
 
3.6 Randomisation 
 
Patients underwent stratified randomisation into EVAC or SC groups based on 
age, gender, hospital site and BCSP status. This was done by means of a 
computer-generated system using a dynamic adaptive algorithm in 
collaboration with North Wales Organisation for Randomised Trials in Health 
(NWORTH) Clinical Trials Unit. 
 
3.7 Participating colonoscopists and training with Endocuff Vision 
 
There was a maximum of 10 colonoscopists per site and colonoscopists were 
chosen to reflect the range of experience. At each site, a limited number 
(maximum 4) of BCSP colonoscopists were selected. All colonoscopists at 
participating units underwent theoretical and practical sessions of training 
(using online/DVD tutorials) with Endocuff Vision and had a lifetime 
experience of at least 20 cases with using the device prior to study 
commencement. A retrospective review of colonoscopists using Endocuff 
identified that a learning curve of 4 procedures seemed to be adequate with the 
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ability to improve ADR from 20% to 54.5% (p=0.03) when looking at 4 
operators 165. At least one colonoscopist from each site attended the training 
day where the study was discussed, use of the Endocuff Vision demonstrated 
and online/DVD tutorials provided for training of other colonoscopists. 
 
3.8 Central training  
 
I organised a central training day which was held on 8th December 2014 and 
attended by all lead colonoscopists and principal research nurses from 
participating sites. As part of my preparations for the training day, I selected 
the venue which was the Endoscopy Unit at North Tees and Hartlepool NHS 
Hospital, distributed and prepared all training material including training 
DVD’s and PowerPoint presentations. Professor Colin Rees led the training day 
which included live endoscopy case demonstrations of the use of Endocuff 
Vision. Mrs Debbie Skelhorn (Quality Assurance and Compliance Lead) and Mr 
David Hunnisett (Information Technology Manager) from NWORTH Clinical 
Trials Unit provided training on the use of randomisation system and data 
entry onto the MACRO database.  
 
This meeting generated multiple valuable ideas that resulted in substantial and 
none-substantial protocol amendments. A substantial protocol amendment was 
made to allow research nurses to have the option of making a phone call to 
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patients that did not live within the geographical reach of their local hospital to 
ensure that they had not encountered any complications because of their 
colonoscopy procedure at the 21-day review. This was necessary as some 
hospitals were tertiary referral centres.    
 
A virtual training package was provided to lead colonoscopists at each site to 
distribute in their respective hospitals as training aids. This consisted of a 
training DVD, which contained copies of all PowerPoint presentations, 
delivered during the training day, a training video on the use of Endocuff 
Vision and all site file documents.  
 
3.9 Local training  
 
I visited individual sites with Mrs Gayle Clifford (Principal research nurse at 
South Tyneside Hospital) to provide further training and carry out site 
initiations.  
 
The principal research nurse and lead colonoscopist for each site including all 
participating trial colonoscopists and research nurses for each unit attended 
this meeting. These visits were pre-arranged with sites in advance, with each 
visit taking an hour and a half. During the visits, the training video was shown 
and I went through the paper Case Report Forms with all attendees. All sites 
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were required to have signed training logs for each trial member confirming 
that training had taken place.   
 
St Marks Hospital in London was the only site that did not receive a site 
initiation visit as they already had sufficient training in the use of Endocuff 
Vision. All participating colonoscopists at St Marks had already used the 
Endocuff Vision more than 20 times prior to involvement in the trial and 
published a small case series on the use of Endocuff Vision in improving ADR 
161.  
 
I also delivered an extra additional local training session to the bowel cancer 
screening specialist nurses at the Durham and Darlington NHS Hospital site as 
they had expressed their interest in participating in the study to the lead 
colonoscopist and wanted to assist in recruiting patients.  
 
3.10 Data collection and data entry  
 
Research nurses and occasionally bowel cancer screening nurses performed 
data collection and captured data in real time onto the paper Case Report 
Form. This method allowed for more accurate documentation especially as the 
research nurses were often supernumerary and did not have to carry out any 
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other duties in the endoscopy room, allowing for the completion of the Case 
Report Forms in a timely and accurate manner.  
 
Research nurses were also responsible for data transfer from the paper Case 
Report Form onto the electronic MACRO database. All research nurses had 
undergone training on the use of Case Report Forms and MACRO database. 
Any missing data points were flagged up by MACRO, identified by NWORTH 
and passed on to myself to investigate and discuss with respective sites. We 
were unable to arrange for all data entry transfer from paper Case Report Form 
to MACRO to be double-checked and verified. However, Mrs Debbie Skelhorn 
from NWORTH carried out regular monitoring visits, which included choosing 
patients at random and comparing patient endoscopy reports and details in the 
medical case notes with the paper Case Report Forms and the electronic 
MACRO database system to check for accuracy. These monitoring visits 
occurred on the week of 8th June 2015 for South Tyneside NHS Foundation 
Trust and North Tees and Hartlepool Hospitals NHS Foundation Trust, week of 
13th July for Northumbria Healthcare NHS Foundation Trust and City Hospitals 
Sunderland NHS Foundation Trust, week of 3rd August for St Mark’s Hospital 
(London North West Healthcare NHS Trust) and week of 24th September for 
County Durham and Darlington NHS Foundation Trust and South Tees 
Hospitals NHS Foundation Trust.  
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3.11 Adverse events 
 
The risks of adverse events for EVAC were believed to be equivalent to SC, 
including bleeding and perforation risks. There were also adverse events related 
to sedation such as cardio-respiratory compromise that were similar in both 
EVAC and SC procedures.  
 
We measured Adverse Events (AEs), which were recorded in patients’ medical 
notes and on case report forms. AEs were recorded for the 21-day period from 
the day of colonoscopy, or until withdrawal from study. Adverse events were 
defined as any new medical occurrence, or worsening of a pre-existing medical 
condition in a patient. There were no known complications or adverse events 
from Endocuff Vision. All AEs were graded as mild, moderate or severe, and 
was assessed by an Investigator to define the relationship to the Endocuff 
Vision.  
 
Serious adverse events (SAEs) were treated clinically as appropriate and 
reported to the trial team within 24 hours of the research team becoming aware 
of the event, using the study specific SAE Form. The main NHS research ethics 
committee were informed of any related and unexpected SAEs within 15 days of 
the trial team becoming aware of the event, using the National Research Ethics 
Service SAE form.  
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An event was serious if it: 
1. Resulted in death  
2. Was life threatening 
3. Resulted in hospitalisation or prolongation of existing hospitalisation 
(Exceptions to this were routine planned admissions, including admission 
for colonoscopy procedures as part of the study) 
4. Lead to persistent significant disability or incapacity 
5. Was otherwise considered to be medically significant by the Investigator 
 
SAEs were recorded and reported from the time of colonoscopy until 21 days 
following the colonoscopy or until the time of withdrawal. SAEs were assessed 
for expectedness, severity and relatedness to the Endocuff Vision device. SAEs 
were followed until resolution, death, or until resolution with sequelae. In 
addition, all SAEs were recorded in the Case Report Form on the Adverse 
Events section. SAEs were reported even if they were expected events or 
unrelated events by the Investigator. 
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3.12 Assessment and follow up 
 
Clinical follow up was performed as per routine clinical practice for each 
respective unit. Colonoscopy related complications were recorded up to 21 days’ 
post procedure. All patients had their post colonoscopy surveillance interval (as 
per British Society of Gastroenterology or Bowel Cancer Screening Programme 
guidelines) recorded in the Case Report Form, where appropriate. In cases of 
incomplete colonoscopy, the reason for this was recorded. Eligible, consented 
patients remained in the study for 21 days following colonoscopy. SAEs were 
reported for the 21-day period post colonoscopy for all patients in the study.  
Complication data and adverse events at 21 days were reviewed by the most 
appropriate method for the population at each local site. This consisted of 
either a phone call to the patient or review of medical notes and hospital 
databases. If a patient was found to have presented to a different hospital post 
procedure to the hospital where the colonoscopy was performed, we contacted 
their General Practitioner to obtain information regarding the event. All units 
were given a 14-day allowance after the end of the 21-day follow up period to 
perform their 21-day review, but only data within the 21-day window was 
included.  No additional visits were required for patients who entered the 
study. All follow up appointments post colonoscopy were arranged as per 
routine care for the respective unit if required. The timescale for the outpatient 
appointments and subsequent care was unaltered by participation in the study. 
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3.13 Sample size  
 
The study was powered to detect a difference in the ADR between two groups. 
In calculating the sample size, we took into consideration that there were 2 
subgroups of participants – those undergoing colonoscopy via the BCSP, and 
those with symptoms or being followed up in the general, non-screening, NHS 
service. ADR varied between these two groups; in the BCSP screening 
population ADR was 46.5%, and in the non-screening population it was 15.9% 
44,48. A difference in ADR of 5-10% would be of clinical importance (5% in the 
non-screening cohort, and 10% in the screening cohort). Preliminary work on 
BCSP participants at one of the Chief Investigators’ sites suggested that such a 
rise in ADR for EVAC procedures was possible. The proportion of screening to 
non-screening participants was anticipated to be approximately 20:80. Mean 
ADR for the whole group was therefore likely to be 21.8%, and a 6% increase in 
ADR to 27.8% was deemed to be clinically significant. Therefore, to 
demonstrate a 6% increase in ADR with a 5% significance level and 90% power 
using a one-sided test it was calculated that 886 patients per group were 
required for the study resulting in 1772 patients in total. 
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3.14 Data analyses 
 
The primary outcome was adenoma detection rate. A chi-square test was used 
to compare this outcome between groups. A secondary outcome was the 
number of adenomas detected per procedure. This was likely to have a 
positively skewed distribution, and so the Mann-Whitney test was used to 
compare between groups. An additional secondary outcome was the proportion 
of patients who required a follow up procedure (based on British Society of 
Gastroenterology adenoma surveillance guidelines), which was be compared 
between groups using the chi-square test. Other secondary outcomes were 
examined on a non-inferiority basis, namely caecal intubation rate, insertion 
time to caecum, withdrawal time in procedures where no polyps were found 
and patient satisfaction. The margin of non-inferiority was set for all outcomes 
which were: 
 
 Caecal intubation rate – 5%  
 Withdrawal time – 1 minute 
 Insertion time – 1 minute 
 Patient satisfaction (nurse assessment of comfort) – 1 point (on 0-9 
scale)  
 Patient satisfaction (Patient experience questionnaire: Binary variables 
Q12, Q15, Q16, Q17, Q18) – 10% 
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 Patient satisfaction (Patient experience questionnaire: Ordinal variables 
Q13, Q14) – 10% in percentage answering ‘agree’ or ‘strongly agree’  
 Patient satisfaction (next day questionnaire) - 1 point (on 0-11 scale) 
 
For the continuous outcomes, one-sided 97.5% confidence interval for the 
mean difference between groups was calculated. For the binary outcomes, a 
one-sided 97.5% confidence interval for the difference in proportions was 
calculated. Non-inferiority was assumed if the bound of the confidence interval 
did not cross the point of non-inferiority. The rate of cuff exchange was 
calculated in the EVAC group, along with a corresponding confidence interval. 
Data analyses were performed on an intention to treat basis. Data and all 
appropriate documentation were stored for a minimum of 15 years after the 
completion of the study, including the follow-up period. Data cleaning was 
performed on a 5% sample of participants randomly selected by the clinical 
trials unit using excel random number generations from each of the seven sites. 
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3.15 Data Monitoring Committee  
 
The trial was supervised by the Data Monitoring Committee, which consisted of 
an independent chair, with 2 independent clinicians and an independent 
statistician. The aim of the Data Monitoring Committee was to safeguard the 
interests of trial participants, assess the safety and viability of the intervention 
during the trial and monitor the overall conduct of the clinical trial. The Data 
Monitoring Committee met every 4 months.  
 
3.16 Trial Management Group 
 
The Chief Investigator had overall responsibility for the study and oversaw all 
study management. The Trial Management Group was responsible for the day 
to day running of the trial. The Trial Management Group was supported by and 
reported to an independent Trial Steering Committee. The Trial Management 
Group met every 2 months.  
 
3.17 Trial Steering Committee  
 
The trial was supervised by the Trial Steering Committee, which consisted of an 
independent chair, independent clinician, patient and public involvement 
representative and an independent statistician. The role of the Trial Steering 
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Committee was to supervise the trial to ensure that the trial was conducted to 
the rigorous standards set out in the Department of Health’s Research 
Governance Framework for Health and Social Care and the principles of Good 
Clinical Practice. The Trial Steering Committee met every 6 months.  
 
3.18 Ethical considerations  
 
Ethical approval was awarded by the North East – York Research Ethics 
Committee prior to the study starting (REC reference 14/NE/1111). There were 
no known additional risks to patients associated with the use of the Endocuff 
Vision device. The addition of Endocuff Vision did not add significantly to the 
duration of the procedure, although if adenoma detection rate increased 
significantly, the procedure would take longer due to increased polypectomy 
numbers. Patients were informed of the risks associated with standard 
colonoscopy and consented for the procedures as per standard clinical practice 
in each centre. In addition, patients completed a study specific consent form 
after discussion with the research team.   
The study was conducted in accordance with the recommendations for 
physicians involved in research on human subjects adopted by the 18th World 
Medical Assembly, Helsinki 1964 and later revisions. The ADENOMA Study was 
supported by the British Society of Gastroenterology Endoscopy Research 
Committee and had been identified as a research priority. The protocol for 
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ADENOMA study was reviewed and endorsed by the Bowel Cancer Screening 
Research Committee. 
 
3.19 Sponsorship and funding 
 
South Tyneside NHS Foundation Trust was the study sponsor. The ADENOMA 
Study was conducted on existing NHS and BCSP lists, at no extra cost to the 
NHS. Funding was provided by ARC Medical Design Ltd to cover Endocuff 
Vision devices, clinical trial unit costs, and results analysis. ARC Medical 
Design Ltd is a company formed by Mr Patrick Axon that designed and 
invented Endocuff Vision.  The two chief investigators of the ADENOMA study 
were full-time dedicated clinical researchers. Principal investigators at each site 
had a research team (of fellows and/or nurses) who recruited participants and 
collected data. No additional NHS resources were required for this study.  
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3.20 My role and responsibilities in this study 
 
I developed the protocol with Professor Colin Rees prior to the start of the trial. 
This involved refining the protocol after performing a basic literature review 
and going through the practicalities of the patient recruitment process with our 
research nurses which allowed for identification of appropriate inclusion, 
exclusion and withdrawal criteria. Data points were chosen based on 
established quality indicators including bowel preparation and withdrawal 
times. I discussed and worked with our trial statistician to identify the sample 
size required and ensured that we had a robust statistical analysis plan in place 
prior to patient recruitment. Any issues identified were corrected with 
amendments sent to relevant ethical and research authorities. I worked closely 
with NWORTH ensuring that the trial protocol and any additional documents 
were accurate and compatible with their electronic systems. This included 
safeguarding clear randomisation procedures, data monitoring and reporting 
systems. I prepared all the standard operating procedure documents for the 
study including pre-attendance to endoscopy, day of procedure and 21-day 
review and adverse events.  
 
I arranged for one-to-one training sessions with all colonoscopists at each site 
in the use of Endocuff Vision and led the training of research nurses in study 
protocol and data collection. This included organising a training day event for 
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all principal investigators and lead research nurses with live demonstrations of 
Endocuff Vision. I ensured that all investigators were trained in Good Clinical 
Practice. In addition, I organised site initiation visits, ensured adequate 
distribution of Endocuff Vision supplies and acted as the first point of contact 
for any queries from participating sites. 
 
During the running of the trial, I recruited patients and collected data at the 
South Tyneside Hospital site with help from the research nurses.  In addition, I 
oversaw the recruitment of patients at the other sites, allowing me to identify 
any issues during recruitment. Any adverse events were identified, escalated 
and investigated appropriately. During the trial, I prepared seven none 
substantial amendments and two substantial amendments which were 
approved by the local ethics committee. I sat on the the Trial Management 
Group and was an observer in the Trial Steering Committee and Data 
Management Committee.  
 
On completion of the trial, I analysed the data with our trial statistician based 
on the statistical analysis plan.  We identified trends in the data which led to 
further subgroup analyses. Once all the results were finalised, I presented the 
findings of this study at local, regional and international meetings. Lastly, I also 
prepared a manuscript for publication in the GUT journal which has been 
accepted and is currently in press.  
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3.21 The role of the Clinical Trials Unit 
 
This trial was supported by the North Wales Organisation for Randomised 
Trials in Health (NWORTH) clinical trials unit. NWORTH provided:  
  
● Electronic database that enabled sites to upload information on recruitment 
data, withdrawals and adverse events reporting. This database was called 
MACRO.   
● Online randomisation system  
● Monitoring visits at the start of the study to ensure compliance with Good 
Clinical Practice principles and trial protocol requirements 
● Site closure visits  
 
3.22 A description of the practical process  
 
All patients referred for colonoscopy at each participating site were sent a 
patient information leaflet for the ADENOMA study at least 24 hours before 
they attended for the procedure. In most sites, this information was sent out 
together with their bowel preparation and instructions for the procedure. The 
information leaflet also contained contact details in case patients had any 
queries before their procedure.   
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On the day of the procedure, patients were approached by the research nurse 
who checked that they had received and read the patient information leaflet. 
After this was confirmed, the research nurse discussed the trial with patients, 
including going through eligibility criteria. Following on from this, patients 
were given the opportunity to read and sign the consent form. A copy of the 
consent form was given to the patient, a copy retained in the patient’s medical 
notes and a copy kept in the trial file.  
 
Subsequently, patients were transported to the endoscopy procedure room 
where the research nurse entered the patient’s details (including age, gender 
and bowel cancer screening programme status) onto the randomisation website 
which determined if the patient was in the ‘control’ group or the ‘intervention’ 
group. This result was relayed to the colonoscopist.  The colonoscopy 
procedure proceeded as routine if the patient was in the control group. If the 
patient was in the intervention group, Endocuff Vision was placed onto the tip 
of the colonoscope before proceeding. The research nurses stayed for the 
duration of the procedure in the endoscopy room and recorded use of sedation, 
position change, start and finish times of procedure, procedural findings and 
patient comfort scores onto a paper Case Report Form (CRF) (Appendix 1).  
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On procedure completion, the research nurse completed the nurse assessment 
comfort score questionnaire (Appendix 1) and the patient assessment of 
comfort questionnaire (see Appendix 1). This was done in either the endoscopy 
room or the endoscopy day ward depending on the level of sedation that the 
patient had received. On discharge from the endoscopy unit, patients were 
given the next day questionnaire (see Appendix 2) together with a pre-paid 
addressed envelope to be completed at home once they have recovered from 
the procedure.  
 
Case Report Forms were filed by research nurses into the trial folder. On the 21-
day review date, the research nurse looked at medical notes and electronic IT 
hospital systems or rang patients to check if they had any complications or 
emergency hospital admissions within that time. We also checked histology 
results for any polyps that were removed. If the patient lived locally, the 
research nurses only looked at medical notes and electronic IT systems. 
However, as some sites were tertiary referral centres, the research nurses rang 
patients that did not live locally to and enquired about any admissions or 
complications to other hospitals. This was documented on the 21-day review 
form (see Appendix 3).   
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Once the 21-day review form was completed, all data were uploaded by the 
research nurse onto MACRO which was an electronic database established by 
NWORTH. The MACRO electronic database was created based on the paper 
CRF and contained all the data points of the paper CRF. All site had a grace 
period of 14 days from the 21-day review date to complete the review and a 
further 28 days’ grace period for data entry onto MACRO. Lastly, any next day 
questionnaires that were returned were also uploaded onto MACRO. Figure 14 
illustrates a flow chart of the recruitment process.  
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Chapter 4: Results 
 
4.1 Descriptive data  
 
Patients were assessed for eligibility prior to recruitment into the study based 
on the specific inclusion and exclusion criteria as described in Table 2.  
Inclusion Criteria  Exclusion Criteria  
1. Age 18 years and 
over 
2. Referral for 
screening, 
surveillance, or 
diagnostic 
colonoscopy 
3. Ability to give 
informed consent 
  
1. Absolute contraindications to colonoscopy  
2. Established or suspicion of large bowel obstruction or 
pseudo-obstruction  
3. Known colon cancer or polyposis syndromes 
4. Known colonic strictures 
5. Known severe diverticular segment (that is likely to 
impede colonoscope passage) 
6. Patients with active colitis (ulcerative colitis, Crohn’s 
colitis, diverticulitis, infective colitis) 
7. Patients lacking capacity to give informed consent 
8. Patients who are on clopidogrel, warfarin, or other 
new generation anticoagulants who have not 
stopped this for the procedure.  
9. Patients who are attending for a therapeutic 
procedure or assessment of a known lesion. 
10. Pregnancy 
Table 2: Inclusion and exclusion criteria 
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 Figure 15: CONSORT trial flow diagram 
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Table 3: Patients excluded from the study  
 
 
 
 
 
 
 
 
 
 
Reasons Number of 
patients 
Gender 
          M                    F 
Age 
Not eligible  909 499 (55%) 410 (45%) 62 (Range 17-98) 
Declined to participate 749 347 (46%) 402 (54%) 63 (Range 17-94) 
Research team 
unavailable 
253 124 (49%) 129 (51%) 61 (Range 22-88) 
Procedure cancelled  139 78 (56%) 61 (44%) 62 (Range 18-88) 
Did not attend 100 60 (60%) 40 (40%) 56 (Range 22-85) 
 Randomisation system 
maintenance 
6 4 (67%) 2 (33%) 67 (Range 60-72) 
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Table 4: Patient demographics for all patients randomised into study  
Factor Both groups 
(n=1772) 
SC 
(n=884) 
EVAC 
(n=888) 
Male 1009 (56.9%) 502 (56.8%) 507 (57.1%) 
Female 763 (43.1%) 382 (43.2%) 381 (42.9%) 
Mean age (SD) 61.9 (11.4) 62.1 (11.1) 61.7 (11.7) 
Age  < 60   546 (30.8%) 273 (30.9%) 273 (30.7%) 
        60-73  1029 (58.1%) 515 (58.3%) 514 (57.9%) 
        74+ 197 (11.1%) 96 (10.9%) 101 (11.4%) 
Previous abdominal surgery   
        No 1089 (61.5%) 542 (61.3%) 547 (61.6%) 
        Yes 683 (38.4%) 342 (38.7%) 341 (38.4%) 
 Recruitment   
        Non-BCSP 975 (55.0%) 481 (54.4%) 494 (55.6%) 
        BCSP 797 (45.0%) 403 (45.6%) 394 (44.4%) 
Indication for colonoscopy  
        Cancer screening 557 (31.4%) 283 (32.0%) 274 (30.9%) 
        Cancer surveillance follow up 177 (10.0%) 88 (10.0%) 89 (10.0%) 
        Colonoscopy conversion 63 (3.4%) 32 (3.6%) 31 (3.5%) 
        Symptomatic diagnostic 703 (39.7%) 346 (39.1%) 357 (40.2%) 
        Symptomatic surveillance 272 (15.4%) 135 (15.3%) 137 (15.4%) 
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Table 5: Patient demographics in non-BCSP subgroup 
 
 
Factor Both groups 
(n=975) 
SC                
(n=481) 
EVAC            
(n=494) 
Male 468 (48.0%) 228 (47.4%) 240 (48.6%) 
Female 507 (52.0%)) 253 (52.6%) 254 (51.4%) 
Mean age (SD) 59.1 (13.9) 59.4 (13.6) 58.7 (14.2) 
Age   < 60   464 (47.6%) 228 (47.4%) 236 (47.8%) 
         60-73  362 (37.1%) 180 (37.4%) 182 (36.8%) 
         74+ 149 (15.3%) 73 (15.2%) 76 (15.4%) 
Previous abdominal surgery 
         No 564 (57.8%) 276 (57.4%) 288 (58.3%) 
         Yes 411 (42.2%) 205 (42.6%) 206 (41.7%) 
Indication for colonoscopy   
        Symptomatic diagnostic 703 (72.1%) 346 (71.9%) 357 (72.3%) 
        Symptomatic surveillance 272 (27.9%) 135 (28.1%) 137 (27.7%) 
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Table 6: Patient demographics in BCSP subgroup 
 
 
Factor 
Both groups 
(n=797) 
SC                
(n=403) 
EVAC         
(n=394) 
Male 541 (67.9%) 274 (68.0%) 267 (67.8%) 
Female 256 (32.1%) 129 (32.0%) 127 (32.2%) 
Mean age (SD) 65.4 (5.5) 65.3 (5.5) 65.5 (5.5) 
Age   < 60   82 (10.3%) 45 (11.2%) 37 (9.4%) 
         60-73  667 (83.7%) 335 (83.1%) 332 (84.3%) 
         74+ 48 (6.0%) 23 (5.7%) 25 (6.4%) 
Previous abdominal surgery 
         No 525 (65.9%) 266 (66.0%) 259 (65.7%) 
         Yes 272 (34.1%) 137 (34.0%) 135 (34.3%) 
Indication for colonoscopy 
         Cancer screening 557 (69.9%) 283 (70.2%) 274 (69.5%) 
         Cancer surveillance follow up 177 (22.2%) 88 (21.8%) 89 (22.6%) 
         Colonoscopy conversion 63 (7.9%) 32 (7.9%) 31 (7.9%) 
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Figure 15 is a flow diagram of the trial recruitment process. A total of 3928 
patients were assessed for eligibility. However, 2156 were excluded with 909 
patients being ineligible and 749 patients declining to participate (Table 3). 
Four hundred and ninety eight patients fell into the ‘other’ category. Of these, 
253 patients had their colonoscopies performed in a list where there was no 
member of the research team available, 139 patients cancelled their procedures 
or had their procedures cancelled by clinicians, 100 did not attend their 
appointment and six had their colonoscopies performed when the 
randomisation online system was undergoing maintenance. However, when 
analysed by gender and mean age, the excluded group of patients were 
comparable to patients recruited into the study,  
 
Table 4 illustrates the patient demographics. Most patients were male with a 
mean age of 62. Most patients did not have previous abdominal surgery. For 
BCSP and non-BCSP subgroups and indications for colonoscopy, patients were 
well matched in both SC and EVAC subgroups (Table 5 and Table 6). 
 
Olympus colonoscopes were used in 1760 patients and Fuji colonoscopes in 12 
patients. However, the use of these two types of colonoscopes were similar in 
both subgroups. A total of 48 colonoscopists participated in the trial, 17 of 
which were BCSP colonoscopists.   
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Table 7: Use of hyoscine-n-butylbromide, carbon dioxide gas, position change and 
rectal retroflexion in all patients   
 
 
Outcome SC           
(n=481) 
EVAC    
(n=494) 
One-sided    
P-value 
Hyoscine-n-butylbromide use  259 (53.9%) 327 (66.2%) <0.001 
 Carbon dioxide gas use 311 (64.7%) 315 (63.8%) 0.61 
Position change 413 (86.0%) 392 (79.8%) 0.99 
Rectal retroflexion 422 (87.7%) 401 (81.2%) 1.00 
 
Table 8: Use of hyoscine-n-butylbromide, carbon dioxide gas, position change and 
rectal retroflexion in non-BCSP subgroup  
Outcome SC             
(n=884) 
EVAC    
(n=888) 
One-sided     
P-value 
Hyoscine-n-butylbromide use  568 (64.3%) 627 (70.6%) 0.002 
 Carbon dioxide gas use 678 (76.7%) 672 (75.7%) 0.69 
Position change 772 (87.5%) 718 (81.3%) 1.00 
Rectal retroflexion 785 (88.8%) 723 (81.4%) 1.00 
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Table 9: Use of hyoscine-n-butylbromide, carbon dioxide gas, position change and 
rectal retroflexion in BCSP subgroup  
 
The use of hyoscine-n-butylbromide and carbon dioxide was compared in both 
groups. The use of hyoscine-n-butylbromide was significantly higher in the 
EVAC arm when all patients were analysed together. Hyoscine-n-butylbromide 
was used in 70.6% of patients in the EVAC arm, compared to only 64.3% in the 
SC arm. A similar significant difference was observed in the non-BCSP patients, 
but no difference between arms was found for the BCSP subgroup. No 
difference between the two study groups was found with carbon dioxide gas use 
in all patients, or in the two main subgroups.  There was no evidence that 
position changes or rectal retroflexion was higher in the EVAC group. These 
outcomes were assessed on a one-sided basis, specifically examining superiority 
Outcome  SC            
(n=403) 
EVAC    
(n=394) 
One-sided   
P-value 
Hyoscine-n-butylbromide use  309 (76.7%) 300 (76.1%) 0.57 
 Carbon dioxide gas use 367 (91.0%) 357 (90.6%) 0.59 
Position change 359 (89.3%) 326 (83.2%) 0.99 
Rectal retroflexion 363 (90.1%) 322 (81.7%) 1.00 
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in the EVAC group. The data suggested lower occurrences of both outcomes in 
the EVAC group.  
 
Table 10: Endocuff Vision removal in all patients 
 
Variable n/ N % (95% CI) 
Endocuff Vision removal 21 / 494 4.3% (2.7%, 6.4%) 
Reasons for removal N % removals 
Angulation in fixed sigmoid colon 13 61.9% 
New diagnosis of polyposis syndrome 0 0.0% 
New diagnosis of active colitis 1 4.8% 
Identification of colonic stricture 3 14.3% 
New cancer diagnosis 2 9.5% 
 
Table 11: Endocuff Vision removal in non-BCSP subgroup 
Variables n/ N % (95% CI) 
Endocuff Vision removal 36 / 887 4.1% (2.9%, 5.6%) 
Reasons for removal N % removals 
Angulation in fixed sigmoid colon 19 52.8% 
New diagnosis of polyposis syndrome 0 0.0% 
New diagnosis of active colitis 1 2.8% 
Identification of colonic stricture 6 16.7% 
New cancer diagnosis 7 19.4% 
  
 
113 
 
Table 12: Endocuff Vision removal in BCSP subgroup 
 
Endocuff Vision was fitted in 887 patients but was subsequently removed in 36 
patients (4.1% of those receiving it). The most common reason for removal was 
angulation in the fixed sigmoid colon, which accounted for just over half (53%) 
of removals. Other reasons for removal included new cancer diagnosis (19% of 
removals) and the identification of colonic stricture (17% of removals). 
Endocuff Vision removal was similar in non-BCSP patients (4.3%) and BCSP 
patients (3.8%). 
 
 
 
 
Variable n/ N % (95% CI) 
Endocuff Vision removal 15 / 393 3.8% (2.2%, 6.2%) 
Reasons for removal N % removals 
Angulation in fixed sigmoid colon 6 40.0% 
New diagnosis of polyposis syndrome 0 0.0% 
New diagnosis of active colitis 0 0.0% 
Identification of colonic stricture 3 20.0% 
New cancer diagnosis 5 33.3% 
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(*) Higher score indicates a lower level of satisfaction 
 
Table 13: Patient scores non-inferiority outcomes – all patients 
 
Outcome SC 
Mean (SD) 
EVAC 
Mean (SD) 
Difference 
(1-sided 97.5% 
CI) 
Non-
inferiority 
margin 
Nurse assessment comfort (0-9 
scale) (*) 
2.6 (2.2) 2.6 (2.2) 0.1 (-°, 0.3) 1 unit 
Next day questionnaire (0-11 
scale) (*) 
3.4 (2.5) 3.6 (2.3) 0.2 (-°, 0.4) 1 unit 
  Given sedation  353 
(67.9%) 
370 (68.4%) 0.5% (-∞, 6.1%) 10% 
 More uncomfortable 
than expected 
115 
(21.8%) 
107 (19.7%) -2.1% (-∞, 2.7%) 10% 
 Camera insertion 
uncomfortable 
79 (15.0%) 128 (23.6%) 8.6% (-∞, 13.3%) 10% 
 Colonoscopy stopped 23 (4.4%) 23 (4.3%) -0.1% (-∞, 2.3%) 10% 
   … satisfied response 21 (91.3%) 23 (100.0%) 8.7% (-2.8%, ∞) 10% 
 Bottom/stomach pain 87 (16.5%) 114 (21.0%) 4.6% (-∞, 9.2%) 10% 
 Bleeding from bottom 40 (7.6%) 50 (9.2%) 1.6% (-∞, 4.9%) 10% 
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(*) Higher score indicates a lower level of satisfaction 
 
Table 14: Patient scores non-inferiority outcomes – non-BCSP subgroup 
 
Outcome SC 
Mean (SD) 
EVAC 
Mean (SD) 
Difference 
(1-sided 97.5% 
CI) 
Non-
inferiority 
margin 
Nurse assessment comfort 
(0-9 scale) (*) 
3.1 (2.2) 3.1 (2.2) 0.1 (∞, 0.3) 1 unit 
Next day questionnaire (0-11 
scale) (*) 
4.1 (2.5) 4.1 (2.3) 0.1 (∞, 0.4) 1 unit 
 Given sedation  195 (75.3%) 209 (74.9%) -0.3% (-∞, 6.9%) 10% 
 More uncomfortable 
than expected 
71 (27.0%) 73 (26.1%) -0.9% (-∞, 6.6%) 10% 
 Camera insertion 
uncomfortable 
49 (18.7%) 81 (29.1%) 10.4% (-∞, 
17.6%) 
10% 
 Colonoscopy stopped 12 (4.6%) 16 (5.8%) 1.2% (-∞, 4.9%) 10% 
   … satisfied response 11 (91.7%) 16 (100.0%) 8.3% (-7.3%, ∞) 10% 
 Bottom/stomach pain 65 (24.7%) 83 (29.8%) 5.0% (-∞, 
12.5%) 
10% 
 Bleeding from 
bottom 
27 (10.3%) 29 (10.3%) 0.0% (-∞, 5.1%) 10% 
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(*) Higher score indicates a lower level of satisfaction 
 
Table 15: Patient scores non-inferiority outcomes – BCSP subgroup 
 
Outcome SC 
Mean (SD) 
EVAC 
Mean (SD) 
Difference 
(1-sided 97.5% 
CI) 
Non-
inferiority 
margin 
Nurse assessment comfort 
(0-9 scale) (*) 
1.9 (2.1) 2.0 (2.0) 0.1 (∞, 0.4) 1 unit 
Next day questionnaire (0-11 
scale) (*) 
2.7 (2.3) 3.0 (2.2) 0.3 (∞, 0.6) 1 unit 
 Given sedation  158 (60.5%) 161 (61.5%) 0.9% (-∞, 9.3%) 10% 
 More uncomfortable 
than expected 
44 (16.6%) 34 (12.9%) -3.7% (-∞, 2.3%) 10% 
 Camera insertion 
uncomfortable 
30 (11.4%) 47 (17.8%) 6.4% (-∞, 
12.4%) 
10% 
 Colonoscopy stopped 11 (4.2%) 7 (2.7%) -1.5% (-∞, 1.6%) 10% 
   … satisfied response 10 (90.9%) 7 (100.0%) 9.1% (-7.9%, ∞) 10% 
 Bottom/stomach pain 22 (8.3%) 31 (11.8%) 3.5% (-∞, 8.6%) 10% 
 Bleeding from 
bottom 
13 (4.9%) 21 (8.0%) 3.1% (-∞, 7.3%) 10% 
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Nurse assessment of the patient comfort and the patients’ satisfaction on the 
next day questionnaire was also evaluated on a non-inferiority basis, with the 
results for all patients summarised in Table 13. Both measures were found to be 
non-inferior in the EVAC arm relative to the SC, with the upper bound of the 
confidence intervals not crossing the margin of non-inferiority. The EVAC 
group was also found to be non-inferior on these measures in both the non-
BCSP patients (Table 14) and BCSP patients (Table 15). 
 
Questions from the Research questionnaire also, asking about patient 
satisfaction, were evaluated on a non-inferiority basis. The results for all 
patients are summarised in Table 13. When all patients were analysed together 
the EVAC was found to be non-inferior on most of the measures assessed. The 
exception was for the question “inserting the camera through the anus was 
uncomfortable”. Here 15.0% of the SC group agreed or strongly agreed with this 
statement, which rose to 23.6% in the EVAC group. The upper bound for a 
confidence interval for the difference between groups was 13.3% which crossed 
the bound of non-inferiority, which was set at 10%. The EVAC group was also 
not found to be non-inferior on this measure in the non-BCSP subgroup (Table 
14), and the BCSP subgroup (Table 15).  
 
Aside from camera comfort, in the non-BCSP group, there non-inferiority was 
also not achieved for the question “after going home I suffered pain in my 
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bottom and/or stomach”. The percentage of patients answering yes to this 
question was 5% higher in the EVAC group, and the confidence interval for the 
difference crossed the 10% non-inferiority margins. All other parameters met 
the criteria for non-inferiority in this subgroup. Aside from the camera comfort, 
already discussed, in the BCSP subgroup all the other measures of patient 
satisfaction were non-inferior in the EVAC group to the SC group. 
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4.2 Primary outcome – adenoma detection rate  
 
(*)  Omitting patients with where Endocuff was not used 
(**) Omitting patients with where Endocuff was not used and where Endocuff was removed 
 
Table 16: Primary outcome, adenoma detection rate – all patients  
 
 
 
 
Key: FE = fixed effects;  RE = random effects 
 
Table 17: Primary outcome, model based sensitivity analyses – all patients  
  
Analysis Adenoma 
detection 
SC 
N (%) 
EVAC 
N (%) 
One-sided 
P-value 
ITT No adenoma 564 (63.8%) 525 (59.1%) 0.02 
  1+ adenomas 320 (36.2%) 363 (40.9%)  
Per Protocol 1 (*) No adenoma 564 (63.8%) 525 (59.2%) 0.02 
  1+ adenomas 320 (36.2%) 362 (40.8%)  
Per Protocol 2 (**) No adenoma 564 (63.8%) 498 (58.5%) 0.01 
  1+ adenomas 320 (36.2%) 353 (41.5%)  
Adjustments Odds Ratio 
(1 sided 95% CI) 
One-sided P-value 
Unadjusted (primary analysis) 1.22 (1.04, ∞) 0.02 
Site (FE), recruitment, age 1.27 (1.07, ∞) 0.01 
Endoscopist (RE), recruitment, age 1.27 (1.07, ∞) 0.01 
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Table 18: Primary outcome – subgroups 
 
 
The primary outcome was adenoma detection rate (ADR) which is the 
detection of one or more adenoma per patient. When all patients were analysed 
using the primary analysis population (ITT population), there was a 
significantly superior ADR in the EVAC group (p=0.02 using a one-sided test). 
The results suggested that 36.2% of patients had an adenoma detected in the 
SC group, compared to 40.9% in the EVAC group. The full details are shown in 
Table 16. The odds of adenoma detection were found to be 22% higher in the 
EVAC group than in the SC group. A significant difference between study 
groups was also observed when the data was analysed on a per protocol basis.  
 
 
 
Subgroup SC EVAC 1-sided 
  N % ADR N % ADR P-value 
BCSP patients 403 50.9% 394 61.7% 0.001 
Non-BCSP patients      
All 481 23.9% 494 24.3% 0.44 
Non-BCSP colonoscopists 411 24.1% 425 23.8% 0.54 
BCSP colonoscopists 70 22.9% 69 27.5% 0.26 
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Table 17 shows several model-based sensitivity analyses using the primary 
analysis population. These also suggested a statistically significant benefit of 
EVAC over SC in terms of ADR, with a similar size of difference between groups 
as the primary analysis.  
 
The difference between study arms was also examined in patient subjects, with 
the results summarised in Table 18. There was a significant benefit of EVAC 
over SC in patients recruited through the BCSP. In this subgroup, adenomas 
were detected in 61.7% of patients in the EVAC group, compared to only 50.9% 
of patients in the SC group. However, there were no differences between study 
groups for patients not recruited through the BCSP. This was the case for all 
non-BCSP patients, and when this group was further split into non-BCSP and 
BCSP colonoscopists.  
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4.3 Secondary outcomes  
(*)  Omitting patients with where Endocuff was not used 
(**) Omitting patients with where Endocuff was not used and where Endocuff was removed 
 
Table 19: Mean adenomas per patient – all patients  
 
Analysis SC EVAC 1-sided 
  N Mean (SD) N Mean (SD) P-value 
ITT analysis 884 0.75 (1.40) 888 0.95 (1.89) 0.02 
PP analysis 1 (*) 884 0.75 (1.40) 887 0.94 (1.89) 0.03 
PP analysis 2 (**) 884 0.75 (1.40) 851 0.96 (1.91) 0.01 
BCSP patients 403 1.20 (1.77) 394 1.59 (2.32) 0.004 
Non-BCSP patients      
All 481 0.37 (0.80) 494 0.44 (1.24) 0.42 
Non-BCSP colonoscopists 411 0.37 (0.80) 425 0.44 (1.28) 0.51 
BCSP colonoscopists 70 0.37 (0.80) 69 0.45 (0.96) 0.28 
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The main secondary outcome was mean adenomas detected per procedure 
(MAP) which calculates the mean of all adenomas detected per patient. The 
analysis results for this outcome are shown in Table 19. When all patients were 
included in the analysis there was a significant difference between the two 
study arms (p=0.02) when using the primary analysis population. A higher 
number of adenomas was detected in the EVAC group (mean 0.95 per patient) 
than in the SC group (mean 0.75 per patient). Similar results were obtained 
from the per protocol analyses. A statistically significant difference in MAP 
between the study groups was observed when the analysis was restricted to 
BCSP patients. MAP was higher in the EVAC arm (mean 1.59 per patient) 
compared to the SC arm (mean 1.20 per patient). No significant difference was 
found between study arms for the non-BCSP patients, either all together, or 
separately for those treated by non-BCSP and BCSP colonoscopists. 
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Outcome SC (n=884) EVAC (n=888) One-sided 
P-value 
Polyp detection  424 (48.0%) 480 (54.1%) 0.005 
Sessile serrated adenoma 10 (1.1%) 20 (2.3%) 0.03 
Cancer - all 20 (2.3%) 36 (4.1%) 0.02 
Cancer - endoscopic 19 (2.2%) 32 (3.6%) 0.03 
Cancer - histology 1 (0.1%) 4 (0.5%) 0.09 
Adenoma in left colon 196 (22.2%) 232 (26.1%) 0.03 
Adenoma in right colon 219 (24.8%) 244 (27.5%) 0.10 
Adenoma 10+ mm 61 (6.9%) 70 (7.9%) 0.21 
Adenoma 6-9 mm 68 (7.7%) 94 (10.6%) 0.02 
Adenoma ≤5 mm 272 (30.8%) 307 (34.6%) 0.04 
Non-polypoid adenoma 206 (23.3%) 226 (25.5%) 0.15 
Polypoid adenoma 87 (9.8%) 100 (11.3%) 0.17 
 
Table 20: Polyp detection (yes/no) – all patients 
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Table 21: Polyp detection (yes/no) – non-BCSP subgroup 
  
Outcome SC (n=481) EVAC (n=494) One-sided 
P-value 
Polyp detection  169 (35.1%) 189 (38.3%) 0.16 
Sessile serrated adenoma 5 (1.0%) 12 (2.4%) 0.05 
Cancer - all 5 (1.0%) 10 (2.0%) 0.11 
Cancer - endoscopic 4 (0.8%) 9 (1.8%) 0.09 
Cancer - histology 1 (0.2%) 1 (0.2%) 0.51 
Adenoma in left colon 64 (13.3%) 71 (14.4%) 0.31 
Adenoma in right colon 66 (13.7%) 74 (15.0%) 0.29 
Adenoma 10+ mm 11 (2.3%) 16 (3.2%) 0.18 
Adenoma 6-9 mm 25 (5.2%) 19 (3.9%) 0.85 
Adenoma ≤5 mm 92 (19.1%) 102 (20.7%) 0.28 
Non-polypoid adenoma 57 (11.9%) 63 (12.8%) 0.33 
Polypoid adenoma 28 (5.8%) 34 (6.9%) 0.25 
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Table 22:  Polyp detection (yes/no) – BCSP subgroup 
 
 
 
Outcome SC (n=403) EVAC (n=394) One-sided 
P-value 
Polyp detection  255 (63.3%) 291 (73.9%) <0.001 
Sessile serrated adenoma 5 (1.2%) 8 (2.0%) 0.19 
Cancer - all 15 (3.7%) 26 (6.6%) 0.03 
Cancer - endoscopic 15 (3.7%) 23 (5.8%) 0.08 
Cancer - histology 0 (0.0%) 3 (0.8%) 0.04 
Adenoma in left colon 132 (32.8%) 161 (40.9%) 0.009 
Adenoma in right colon 153 (38.0%) 170 (43.2%) 0.07 
Adenoma 10+ mm 50 (12.4%) 54 (13.7%) 0.29 
Adenoma 6-9 mm 43 (10.7%) 75 (19.0%) <0.001 
Adenoma ≤5 mm 180 (44.7%) 205 (52.0%) 0.02 
Non-polypoid adenoma 149 (37.0%) 163 (41.4%) 0.10 
Polypoid adenoma 59 (14.6%) 66 (16.8%) 0.21 
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Table 23: Polyp detection (number of polyps) – all patients  
 
 
 
Outcome SC (n=884) 
Mean (SD) 
EVAC (n=888) 
Mean (SD) 
One-sided 
P-value 
Polyp detection  1.16 (1.87) 1.49 (2.43) 0.004 
Sessile serrated adenoma 0.017 (0.174) 0.024 (0.159) 0.03 
Cancer - all 0.02 (0.15) 0.04 (0.20) 0.02 
Cancer - endoscopic 0.02 (0.15) 0.04 (0.19) 0.03 
Cancer - histology 0.001 (0.03) 0.005 (0.07) 0.09 
Adenoma in left colon 0.33 (0.77) 0.40 (0.90) 0.02 
Adenoma in right colon 0.42 (0.92) 0.54 (1.38) 0.08 
Adenoma 10+ mm 0.08 (0.32) 0.08 (0.31) 0.22 
Adenoma 6-9 mm 0.10 (0.43) 0.14 (0.49) 0.02 
Adenoma ≤5 mm 0.06 (1.12) 0.72 (1.55) 0.03 
Non-polypoid adenoma 0.39 (0.90) 0.45 (1.08) 0.15 
Polypoid adenoma 0.12 (0.40) 0.14 (0.47) 0.16 
  
 
128 
 
Table 24: Polyp detection (number of polyps) – non-BCSP subgroup  
 
 
 
Outcome SC (n=481) 
Mean (SD) 
EVAC (n=494) 
Mean (SD) 
One-sided 
P-value 
Polyp detection  0.66 (1.20) 0.82 (1.74) 0.14 
Sessile serrated adenoma 0.015 (0.151) 0.024 (0.154) 0.05 
Cancer - all 0.01 (0.10) 0.02 (0.14) 0.11 
Cancer - endoscopic 0.01 (0.09) 0.02 (0.13) 0.09 
Cancer - histology 0.002 (0.05) 0.002 (0.04) 0.51 
Adenoma in left colon 0.16 (0.46) 0.18 (0.51) 0.30 
Adenoma in right colon 0.20 (0.61) 0.26 (1.01) 0.30 
Adenoma 10+ mm 0.02 (0.15) 0.03 (0.19) 0.18 
Adenoma 6-9 mm 0.06 (0.26) 0.04 (0.20) 0.85 
Adenoma ≤5 mm 0.29 (0.71) 0.36 (1.11) 0.26 
Non-polypoid adenoma 0.17 (0.57) 0.19 (0.63) 0.35 
Polypoid adenoma 0.06 (0.27) 0.07 (0.28) 0.25 
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Table 25: Polyp detection (number of polyps) – BCSP subgroup 
 
 
 
 
Outcome SC (n=403) 
Mean (SD) 
EVAC (n=394) 
Mean (SD) 
One-sided 
P-value 
Polyp detection  1.77 (2.30) 2.32 (2.87) 0.001 
Sessile serrated adenoma 0.020 (0.199) 0.023 (0.166) 0.20 
Cancer - all 0.04 (0.19) 0.07 (0.25) 0.03 
Cancer - endoscopic 0.04 (0.19) 0.06 (0.23) 0.08 
Cancer - histology 0.000 (0.000) 0.008 (0.09) 0.04 
Adenoma in left colon 0.53 (0.98) 0.68 (1.17) 0.01 
Adenoma in right colon 0.70 (1.15) 0.90 (1.66) 0.05 
Adenoma 10+ mm 0.15 (0.44) 0.15 (0.41) 0.32 
Adenoma 6-9 mm 0.16 (0.56) 0.26 (0.67) <0.001 
Adenoma ≤5 mm 0.89 (1.40) 1.17 (1.88) 0.01 
Non-polypoid adenoma 0.65 (1.13) 0.78 (1.39) 0.10 
Polypoid adenoma 0.18 (0.51) 0.23 (0.62) 0.18 
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In addition to adenoma detection, the overall polyp detection and detection of 
different adenoma types was compared between groups. 
 
The results when all patients were analysed together are summarised in Table 
20. There were significant differences between arms in terms of overall polyp 
detection. This was higher in the EVAC arm (54.1% of patients) than in the SC 
arm (48.0%) of patients. Occurrence of sessile serrated adenomas and all 
cancers and endoscopic cancers were also significantly higher in the EVAC arm. 
Cancers were found in 4.1% of patients in the EVAC arm, but in 2.3% in the SC 
arm. 
 
The two groups were found to significantly differ in terms of the presence of 
adenomas in the left colon, although there was no difference in adenomas in 
the right colon. Left colon was defined as transverse colon, splenic flexure, 
descending colon, sigmoid and rectum. Right colon was defined as caecum, 
ascending colon and hepatic flexure. Left colon adenomas were significantly 
higher in the EVAC arm (26.1% of patients, compared to 22.2% in the SC 
group). There was no difference between groups for large adenomas (10+mm), 
but there were significantly more patients with an adenoma of 6-9mm and of 
≤5mm in the EVAC. 10.6% of patients in the EVAC group had an adenoma of 6-
9mm, compared to 7.7% in the SC group. The presence of non-polypoid and 
polypoid adenomas was not found to significantly differ between groups.  
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The results for the for the number of polyps/adenomas for all patients 
combined is shown in Table 20. The results mirrored those for the presence of 
different types of polyps.  The overall number of polyps, the number of sessile 
serrated adenomas, the number of all cancers and the number of endoscopic 
cancers were all significantly higher in the EVAC group. The number of 
adenomas in the left colon was significantly higher in the EVAC arm, whilst the 
difference in the right colon did not reach statistical significance. There were 
more medium sized (6-9mm) and small (≤5mm) adenomas in the EVAC group, 
but the groups did not significantly vary in terms of the number of large polyps.  
 
In Table 21 and 24, analyses were repeated for non-BCSP patients. The results 
suggested no strong evidence that any of the variables varied between the two 
study groups. There was slight evidence that the presence and number of 
sessile serrated adenomas was higher in the EVAC arm. However, these results 
were of borderline statistical significance.  
 
In Table 22 and 25, analyses were performed for BCSP patients. The proportion 
of patients with a polyp detected was higher in the EVAC arm, as was the 
number of polyps. There was a mean of 2.9 polyps detected in the EVAC arm, 
compared to 2.3 polyp in the SC arm. The number of cancers overall, and 
proportion of patients with a cancer, was also significantly higher in the EVAC 
arm. Cancers were detected in 3.7% of patients in the SC arm, whilst they were 
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detected in 6.6% of patients in the EVAC arm.  Additionally, the presence and 
number of cancers detected through histology was high in the EVAC arm, but 
the difference in endoscopic cancers was not quite statistically significant. The 
number and presence of sessile serrated adenomas did not vary between study 
arms in this subgroup.  
 
As with the analysis of all patients, the presence of adenomas in the left colon, 
medium sized adenomas and small adenomas were all significantly more 
common in the EVAC arm. The number of these types of adenomas were also 
significantly higher. 40.9% of patients had an adenoma in the left colon in the 
EVAC group, compared to 32.8% of patients in the SC group.  Additionally, 
there was slight evidence that the presence and number of adenomas in the 
right colon was higher in the EVAC arm, but this difference did not quite reach 
statistical significance.  
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Figures are median (IQR) and median difference, or N (%) and % difference 
(*) Including patients not reaching the caecum 
(+) Figures for patients where no polyps were found  
 
Table 26: Insertion and sedation non-inferiority outcomes – all patients  
 
Outcome SC 
 
EVAC Difference 
(1-sided 
97.5% CI) 
Non-
inferiority 
margin 
Reached caecum  458 (95.2%) 474 (96.0%) 0.7% (-1.8%, ∞) 5% 
Insertion 12 (8, 17) 10 (7, 14) -2 (-∞, -1) 1 minute 
Insertion (all) (*) 12 (8, 18) 10 (7, 15) -2 (-∞, -1) 1 minute 
Withdrawal (+) 7 (5, 10) 7 (5, 10) 0 (-∞, 1) 1 minute 
Entonox 209 (43.5%) 180 (36.4%) -7.0% (-∞, -0.9%) 10% 
IV sedation 349 (72.6%) 357 (72.3%) -0.3% (-∞, 5.3%) 10% 
IV analgesia 342 (71.1%) 360 (72.9%) 1.8% (-∞, 7.4%) 10% 
Figures are median (IQR) and median difference, or N (%) and % difference 
(*) Including patients not reaching the caecum 
(+) Figures for patients where no polyps were found  
 
Table 27: Insertion and sedation non-inferiority outcomes – non-BCSP subgroup 
Outcome SC 
 
EVAC Difference 
(1-sided 
97.5% CI) 
Non-
inferiority 
margin 
Reached caecum  852 (96.4%) 858 (96.7%) 0.4% (-1.3%, ∞) 5% 
Insertion 9 (6, 15) 8 (5, 12) -1 (-∞, 0) 1 minute 
Insertion (all) (*) 9 (6, 16) 8 (6, 13) -1 (-∞, 0) 1 minute 
Withdrawal (+) 8 (6, 11) 8 (6, 10) 0 (-∞, 0) 1 minute 
Entonox 291 (32.9%) 283 (31.9%) -1.0% (-∞, 3.3%) 10% 
IV sedation 591 (66.9%) 586 (66.1%) -0.8% (-∞, 3.6%) 10% 
IV analgesia 582 (65.8%) 588 (66.3%) 0.5% (-∞, 4.9%) 10% 
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Outcome SC 
 
EVAC Difference 
(1-sided 
97.5% CI) 
Non-
inferiority 
margin 
Reached caecum  394 (97.8%) 384 (97.7%) -0.1% (-2.1%, ∞) 5% 
Insertion 6 (4, 11) 7 (4, 10) 0 (-∞, 1) 1 minute 
Insertion (all) (*) 7 (4, 11) 7 (5, 10) 0 (-∞, 1) 1 minute 
Withdrawal (+) 9 (7, 12) 8 (6, 10) -1 (-∞, 0) 1 minute 
Entonox 82 (20.4%) 103 (26.2%) 5.9% (-∞, 11.7%) 10% 
IV sedation 242 (60.1%) 229 (58.3%) -1.8% (-∞, 5.0%) 10% 
IV analgesia 240 (59.6%) 228 (58.0%) -1.5% (-∞, -5.3%) 10% 
Figures are median (IQR) and median difference, or N (%) and % difference 
(*) Including patients not reaching the caecum 
(+) Figures for patients where no polyps were found  
 
Table 28: Insertion and sedation non-inferiority outcomes – BCSP subgroup 
 
The results for reaching the caecum, insertion, withdrawal times along with the 
use of analgesia/sedation are shown for all patients in Table 26. The results 
suggested than the EVAC met the criteria for non-inferiority relative to the SC 
group, based on the pre-defined non-inferiority margins, for these outcomes. 
Additionally, EVAC was non-inferior to SC for all these outcomes in the non-
BCSP subgroup (Table 27) and most outcomes for the BCSP subgroup (Table 
28). The exception for the BCSP subgroup was for use of Entonox, where the 
use of Entonox was not non-inferior in the EVAC group. 
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Bowel preparation SC EVAC 
Excellent preparation 143 (16.2%) 146 (16.4%) 
Good preparation 444 (50.2%) 453 (51.0%) 
Adequate preparation 195 (22.1%) 214 (24.1%) 
Poor preparation 102 (11.5%) 75 (8.5%) 
 
Table 29: Bowel preparation scores in both groups  
 
The Bowel Cancer Screening Programme four-point scale was used to assess 
quality of bowel preparation in this study70. Bowel preparation was found to be 
of an equivalent standard in both groups as illustrated in Table 29. 
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Patient group Study arm ADR - First 20% 
n/N (%) 
ADR – Last 20% 
n/N (%) 
P-value 
All  SC 66/165 (40.0%) 65/177 (36.7%) 0.53 
  EVAC 72/184 (39.1%) 68/170 (40.0%) 0.87 
Non-BCSP patients SC 21/91 (23.1%) 25/95 (26.3%) 0.61 
  EVAC 22/106 (20.8%) 23/89 (25.8%) 0.40 
BCSP patients SC 45/74 (60.8%) 40/82 (48.8%) 0.13 
  EVAC 50/78 (64.1%) 45/81 (55.6%) 0.27 
 
Table 30: Comparison of ADR in first and last 20% of cases  
 
An additional analysis defined in the SAP was to compare the ADR between the 
first 20% and last 20% of cases for each endoscopist. The analysis results are 
summarised in Table 30. This shows no statistically significant difference in 
ADR between the first and last 20% of cases for either study arm. This result 
was found for all patients combined, and when split by route of recruitment.  
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Endoscopist ADR Pre-trial 
n/N (%) 
ADR 
SC n/N (%) 
Change 
% (95% CI) 
P-value 
1 34/85 (40.0%) 19/40 (47.5%) 7.5% (-11.2%, 26.2%) 0.43 
2 59/139 (42.5%) 11/26 (42.3%) -0.1% (-20.8%, 20.6%) 0.99 
3 71/243 (29.2%) 6/22 (27.3%) -1.9% (-21.4%, 17.5%) 0.85 
4 119/375 (31.7%) 29/82 (35.4%) 3.6% (-7.7%, 15.0%) 0.52 
5 94/205 (45.9%) 18/33 (54.6%) 8.7% (-9.6%, 27.0%) 0.35 
6 142/231 (61.5%) 24/38 (63.2%) 1.7% (-14.9%, 18.3%) 0.84 
7 112/213 (52.6%) 16/24 (66.7%) 14.1% (-5.9%, 34.1%) 0.19 
8 67/165 (40.6%) 23/36 (63.9%) 23.3% (5.9%, 40.6%) 0.01 
9 25/194 (12.9%) 3/15 (15%) 2.1% (-14.2%, 18.5%) 0.79 
10 50/89 (56.2%) 29/60 (48.3%) -7.8 (-24.2%, 8.5%) 0.35 
11 21/118 (17.8%) 7/36 (19.4%) 1.6% (-13.0%, 16.3%) 0.82 
12 23/59 (39.0%) 26/75 (34.7%) -4.3% (-20.8%, 12.1%) 0.61 
13 9/53 (17.0%) 6/26 (23.1%) 6.1% (-13.0%, 25.2%) 0.52 
14 21/104 (20.2%) 6/23 (26.1%) 5.9% (-13.6%, 25.4%) 0.53 
 
Table 31: Comparison of ADR in the 6 months pre-trial to ADR in the SC arm 
 
Table 31 illustrates the ADR of each endoscopist 6 months before the trial 
period and compared this with their ADR when scoping patients undergoing 
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standard colonoscopy as part of the trial. This was done to assess for the 
Hawthorne effect. We were only able to obtain pre-trial ADR for 14 
endoscopists but only found a significant increase in ADR for one endoscopist 
by 23.3%.  
 
 
Figure 16: Surveillance guidelines after adenoma removal164  
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Patient group Risk SC 
N (%) 
EVAC 
N (%) 
2-sided 
P-value 
All patients No adenoma 564 (63.8%) 525 (59.1%) 0.03 
 Low 205 (23.2%) 225 (25.3%)  
 Intermediate 87 (9.8%) 95 (10.7%)  
 High 28 (3.2%) 43 (4.8%)  
Non-BCSP No adenoma 366 (76.1%) 374 (75.7%) 0.78 
 Low 93 (19.3%) 89 (18.0%)  
 Intermediate 18 (3.7%) 25 (5.1%)  
 High 4 (0.8%) 6 (1.2%)  
BCSP No adenoma 198 (49.1%) 151 (38.3%) 0.004 
 Low 112 (27.8%) 136 (34.5%)  
 Intermediate 69 (17.1%) 70 (17.8%)  
 High 24 (6.0%) 37 (9.4%)  
 
Table 32: Patient risk group according to British Society of Gastroenterology 
surveillance guidelines164 
 
In Table 32, patients were grouped into risk groups based on British Society of 
Gastroenterology surveillance guidelines (Figure 16). In the BCSP subgroup, 
EVAC significantly increased the number of patients in the high risk group by 
3.4% which would increase the colonoscopy workload as these patients have to 
undergo repeat colonoscopy at 1 year.  
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4.4 Adverse events and serious adverse events 
 
Adverse events were defined as any new medical occurrence, or worsening of a 
pre-existing medical condition in a patient and were graded as mild, moderate 
or severe. An event was a serious adverse event when it: 
 Resulted in death 
 Was life threatening 
 Resulted in hospitalisation or prolongation of existing hospitalisation 
(exceptions to this were routine planned admissions, including 
admission for colonoscopy as part of this study) 
 Led to persistent significant disability or incapacity 
 Was otherwise considered to be medically significant by the trial team 
 
All adverse and serious adverse events were reported from the time of 
colonoscopy until 21 days following the colonoscopy or until time of withdrawal 
from the trial. All adverse events and serious adverse events were reported to 
the trial team and assessed for expectedness, severity and relatedness to 
Endocuff Vision. Serious adverse events were followed until resolution, death or 
until resolution with sequelae. In addition, all adverse and serious adverse 
events were reported to the chair of the Data Monitoring Committee who in 
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turn discussed these events with 2 independent clinicians who assessed the 
relationship of these events to Endocuff Vision.    
 
There were 6 serious adverse events (Table 33) and 17 adverse events (Table 34) 
reported during the trial. These were all reported promptly to the principle and 
chief investigators and were independently reviewed by the chair of the Data 
Monitoring Committee and two independent clinicians and felt unlikely to be 
related to Endocuff Vision.  
 
There was an equal distribution of serious adverse events in both the 
intervention and control group. In the intervention group, none of the serious 
adverse events were attributed to Endocuff Vision.  
 
In the adverse events group, there were marginally more events reported in the 
control group compared to the intervention group. No obvious trends were 
seen in both groups.    
 
 
 
 
 
  
 
142 
Serious Adverse Events: Intervention Group 
1 Patient ID 
Date of colonoscopy 
Date of event  
: 101051 
: 23/02/2015 
: 26/02/2015 
Seen in clinic routinely 26/02/15 with lower abdominal 
pain, vomiting, weight loss and dehydration and was 
admitted to the ward. Chest and abdominal computed 
tomography scan found a left breast lesion. Patient was 
also treated for urinary tract infection and discharged 
6/3/15 
2 Patient ID 
Date of colonoscopy 
Date of event  
: 101323 
: 14/09/2015 
: 05/10/2015 
Admitted with sudden onset chest pain on 5/10/15 and 
was admitted to the medical ward. Patient had history 
of previous myocardial infarction in 2014. Chest x-ray, 
electrocardiogram and troponin blood test was all 
normal. Patient was discharged 8/10/15 with cardiology 
follow up. 
3 Patient ID 
Date of colonoscopy 
Date of event  
: 671412 
: 19/01/2016 
: 07/02/2016 
Admitted to hospital 7/2/16 after presenting with 
epigastric abdominal pain and chest pain. Patient was 
diagnosed with acute gallstone cholangitis and given 
antibiotics. Patient was discharged 17/2/16 from 
hospital and was arranged for endoscopic retrograde 
cholangio-pancreatography on the 9/3/16.  
Serious Adverse Events: Control Group 
1 Patient ID 
Date of colonoscopy 
Date of event  
: 101032 
: 22/01/2015 
: 22/01/2015 
Patient was discharged from unit following endoscopic 
mucousal resection, attended 1 hour later with 
abdominal pain, admitted overnight for analgesia and 
antibiotics, abdominal computed tomography scan was 
normal. Patient was diagnosed with post polypectomy 
syndrome and discharged the next day.   
2 Patient ID 
Date of colonoscopy 
Date of event  
: 785014 
: 13/05/2015 
: 27/05/2015 
Admitted to hospital with rectal bleeding, abdominal 
pain and diarrhoea. Had bloods, stool sample, 
abdominal ultrasound and a repeat colonoscopy on 
1/6/15 which reported campylobacter colitis. 
Discharged 5/6/15.   
3 Patient ID 
Date of colonoscopy 
Date of event  
: 558025 
: 04/11/2015 
: 15/11/2015 
Patient presented to A&E, found to have low 
haemoglobin of 56. Had upper gastrointestinal 
endoscopy on 16/11/15 which found an ulcerated 
lesion adjacent to gastric fundus which was treated with 
argon plasma therapy. This was confirmed on histology 
later to be high grade neuroendocrine tumour. Patient 
was discharged on 18/11/15 with plans for palliative 
chemotherapy. 
 
Table 33: Serious Adverse Events  
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Adverse Events: Intervention Group 
1 Patient ID 
Date of colonoscopy 
Date of event  
: 671005 
: 19/01/2015 
: 19/01/2015 
Had abdominal pain for 11 days after procedure, saw GP, 
reassured and pain settled.   
2 Patient ID 
Date of colonoscopy 
Date of event  
: 101051 
: 23/02/2015 
: 11/03/2015 
Attended A&E with slurred speech, reduced mobility, 
bloods and electrocardiogram normal, discharged same 
day 
3 Patient ID 
Date of colonoscopy 
Date of event  
: 101163 
: 21/05/2015 
: 24/05/2015 
Attended A&E with a possible seizure, bloods and X-rays 
normal, patient admitted alcohol excess, discharged same 
day with referral to seizure clinic 
4 Patient ID 
Date of colonoscopy 
Date of event  
: 101163 
: 21/05/2015 
: 05/06/2015 
Attended GP for lethargy, had bloods, found to have 
thyrotoxicosis, given carbimazole and beta blocker, 
referred to endocrinologist 
5 Patient ID 
Date of colonoscopy 
Date of event  
: 101487 
: 31/12/2015 
: 07/01/2016 
Went to A&E with back pain after putting up fence, 
examination normal, discharged with analgesia. 
6 Patient ID 
Date of colonoscopy 
Date of event  
: 101494 
: 04/01/2016 
: 07/01/2016 
Attended A&E with abdominal pain, has a known healing 
enterocutaneous fistula from previous laparotomy, 
reassured fistula looked fine and was drying up, 
discharged 
7 Patient ID 
Date of colonoscopy 
Date of event  
: 671409 
: 11/01/2016 
: 13/01/2016 
Had abdominal pain and wind 2 days post colonoscopy, 
went to A&E, had CXR normal, bloods normal, given 
peppermint solution and discharged home the same day 
8 Patient ID 
Date of colonoscopy 
Date of event  
: 101525 
: 22/01/2016 
: 31/01/2016 
Went to A&E with right knee pain, no trauma history, 
diagnosed with soft tissue injury, given analgesia and 
discharged same day 
Adverse Events: Control Group 
1 Patient ID 
Date of colonoscopy 
Date of event  
: 101012 
: 16/12/2014 
: 17/12/2014 
Attended A&E with abdominal pain, bloods and X-rays 
normal, discharged same day 
2 Patient ID 
Date of colonoscopy 
Date of event  
: 101073 
: 16/03/2015 
: 31/03/2015 
Attended A&E with chest pain, bloods and X-rays 
normal, discharged same day 
3 Patient ID 
Date of colonoscopy 
Date of event  
: 101085 
: 19/03/2015 
: 13/04/2015 
Attended A&E with shortness of breath, chest and back 
pain, bloods and electrocardiogram normal, discharged 
same day 
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4 Patient ID 
Date of colonoscopy 
Date of event  
: 101204 
: 15/06/2015 
: 06/07/2015 
Attended A&E with abdominal pain, bloods normal, 
discharged same day with outpatient abdominal 
ultrasound arranged which was normal 
5 Patient ID 
Date of colonoscopy 
Date of event  
: 558011 
: 10/08/2015 
: 13/08/2015 
Presented to GP with muscular pains down both legs 
from buttocks to mid-calf. GP performed bloods, urine 
tests and physical examination, diagnosed muscular 
pain and prescribed analgesia. 
6 Patient ID 
Date of colonoscopy 
Date of event  
: 671338 
: 13/10/2015 
: 16/10/2015 
Patient reported spotting of blood on wiping bottom. 
This had happened on several episodes prior to his 
colonoscopy as he was undergoing treatment for 
prostate cancer. He saw the GP who confirmed that the 
spotting of blood was likely to be due to prostate 
treatment. 
7 Patient ID 
Date of colonoscopy 
Date of event  
: 101429 
: 17/11/2015 
: 01/12/2015 
Went to A&E with shortness of breath, tight chest, 
productive cough. Had bloods, treated as pneumonia, 
discharged same day with antibiotics and steroids 
8 Patient ID 
Date of colonoscopy 
Date of event  
: 101537 
: 01/02/2016 
: 19/02/2016 
Went to A&E having fainted with abdominal pain (has a 
background of longstanding intermittent abdominal 
pain). Bloods and observations normal, patient 
reassured and discharged same day 
9 Patient ID 
Date of colonoscopy 
Date of event  
: 101543 
: 02/02/2016 
: 02/02/2016 
Went to A&E with fever, chills and abdominal pain. 
Patient had a cold before colonoscopy was performed. 
CXR normal. Discharged same day with antibiotics 
 
Table 34: Adverse events  
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4.5 Trend analysis  
 
Patients who underwent Endocuff Vision-assisted colonoscopy (EVAC) had a 
significantly higher adenoma detection rate by 4.7% when analysed on an 
intention to treat basis. A significant improvement in ADR in the EVAC group 
was also observed when analysed on a per protocol basis. When analysed on a 
model based sensitivity analysis adjusted by site, endoscopist, indication for 
procedure or age, there was statistically significant difference with EVAC over 
standard colonoscopy (SC). When divided into subgroups, it is clear that a 
significant improvement in ADR was only seen in BSCP patients. There was no 
significant improvement in ADR in the non-BCSP subgroup even when these 
patients were scoped by BCSP colonoscopists. This pattern was repeated for 
mean adenomas per patient (MAP), polyp detection, sessile serrated adenomas, 
cancers, left colon adenomas and small and diminutive adenomas. Each of 
these demonstrated a significant improvement in the EVAC arm but when 
analyses were repeated for subgroups, the results were only statistically 
significant in BCSP patients.  
 
The use of hyoscine-n-butylbromide was significantly higher in the EVAC arm 
and was used in 70.6% procedures. There was no significant difference in the 
use of carbon dioxide insufflation, position change or rectal retroflexion.  In 
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addition, there was no statistically significant difference in endoscopist ADR 
between the first and last 20% of cases for either study arm. We also analysed 
the ADR of each endoscopist 6 months before the trial period and compared 
this with their ADR when scoping patients undergoing standard colonoscopy to 
assess for the Hawthorne effect. There was only a significant increase in ADR 
for one endoscopist by 23.3%.  
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Chapter 5: Discussion and Conclusions 
 
5.1 Main findings and outcomes 
 
This study demonstrated that Endocuff Vision (EV) significantly improved 
adenoma detection rate (ADR). The difference in ADR in the EVAC arm was 
predominantly seen in BCSP patients who were scoped by BCSP colonoscopists. 
This group of patients have undergone faecal occult blood testing (FOBt) and 
found to be positive. Consequently, they may have higher rates of pathology 
compared to patients who undergo colonoscopy for various reasons unrelated 
to screening. These results suggest that EV improves visualisation and 
detection of adenomas in a population where they are commonly found.  
 
Adenoma detection also relies heavily on individual colonoscopists being 
vigilant in spotting adenomas, understanding and recognising relevant 
pathology and being rigorous in removing small lesions. All these factors are 
characteristic of BCSP colonoscopists but perhaps less so for non-BCSP 
colonoscopists. Interestingly, in this study we found that in the non-BCSP 
population, there was no significant difference in ADR when patients were 
scoped by BCSP colonoscopists so it may be that Endocuff Vision improves 
ADR in the right patient population instead of being skill dependant. ADR in 
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both subgroups was higher than predicted but similar to current national 
averages. This most likely reflects the ongoing improving practice in UK 
colonoscopy but may also represent improved performance in a trial setting.  
 
Currently ADR is the main marker of colonoscopy quality and a 1% increase in 
ADR is associated with a 3% reduction in interval colorectal cancer and 5% 
reduction in risk of fatal interval colorectal cancer 62. If applied to this study, EV 
could potentially reduce the risk of interval colorectal cancer by 14%. It is not 
possible currently to quantify the effect of an 11% rise in ADR in FOBt positive 
BCSP patients as no data exist on long term outcomes.  
 
The benefits of improving ADR on reduced interval colorectal cancer rates have 
all been demonstrated in populations directly screened by colonoscopy.  In 
addition, the ceiling at which further improvements in ADR confer no 
additional patient benefit has not yet been established nor is a ‘device assisted’ 
ADR known. A rise of 11% in ADR in an RCT is, however, highly significant and 
is likely to be associated with significant clinical benefit.  
 
EV differs from the original Endocuff with the removal of the second row of 
projections and lengthening the remaining row of projections by 2mm resulting 
in a more streamlined device that improves manoeuvrability and allows 
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improved visualisation on withdrawal. These improvements may explain why 
this study illustrated an improvement in ADR with EV use which was not 
reported with the Dutch RCT of the original Endocuff 159.  
 
5.2 Secondary outcomes and findings  
 
Mean adenomas detected per procedure (MAP) was also found to be higher 
with EVAC. ADR is the most widely used marker of quality but the importance 
of MAP is growing as high quality colonoscopy should find all adenomas in a 
patient. MAP measures this, unlike ADR where finding a single adenoma 
positively affects this key performance indicator. Improvement in both ADR 
and MAP in this study suggest genuine clinical benefit associated with EV use. 
EV is the upgraded, second generation model of the original Endocuff. It works 
by flattening haustral fold and the increased detection of adenomas with EV 
was in the left colon, the area where colonic folds are most prominent. EV did 
not confer additional detection in the right colon. EV improved detection of 
small and diminutive polyps but perhaps unsurprisingly not larger polyps. The 
improvement in cancer detection with EV is surprising and in contrast to this. 
EV might be expected to hold back folds and find smaller lesions but appears to 
have also improved detection of larger lesions.  
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Previous studies have demonstrated that whilst the greatest miss rates are for 
small lesions, miss rates for large lesions are still significant 59, therefore the 
improved cancer detection may be a true effect. EV also increased detection of 
sessile serrated adenomas, however this was a small change and the clinical 
significance of this should not be over interpreted.  
 
It is important that devices attached to colonoscopes do not cause harm by 
hindering the procedure, increasing discomfort or causing adverse events. In 
addition, it is important that the devices do not require frequent removal.  The 
EV cuff removal rate of 4.1% is at an acceptably low level. EV did not hinder 
colonic intubation and intubation time was quicker.  
 
It is likely that the EV flattened haustral folds which allowed for quicker and 
easier mucosal inspection, without the need for position change. Use of 
hyoscine-n-butylbromide was higher in the EVAC arm. Colonic spasm may 
hinder insertion during any colonoscopy and this may be more of a hindrance 
when EV is in use. Hyoscine-n-butylbromide is used widely in BCSP and this is 
likely to explain the increased use in this group. EV use was safe and did not 
cause any adverse events in this trial.  
 
EVAC was non-inferior in almost all measures of patient experience. Overall 
patients reported no difference in experience scores between SC and EVAC. 
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When directly asked regarding anal insertion, EVAC anal intubation was 
reported to be slightly more uncomfortable.  Where colonoscopy is undertaken 
under deep sedation this is less likely to be an issue but where light or no 
sedation is used, attention should be given to cuff lubrication and gentle 
insertion technique to minimise discomfort.  
 
5.3 Implications of this research  
 
The ADENOMA study was the first multicentre, randomised controlled trial 
comparing Endocuff Vision-assisted colonoscopy with standard colonoscopy in 
patients attending for symptomatic, surveillance and Bowel Cancer Screening 
Programme colonoscopy. It is the first study to demonstrate improved ADR 
with Endocuff Vision. As ADR is the most important contemporaneous marker 
of colonoscopy quality and low ADR is strongly linked to higher interval 
colorectal cancer rates, this is a significant finding with major potential clinical 
impact 47. In a Polish screening study, the hazard ratio for interval colorectal 
cancer where the colonoscopist had an ADR of less than 20% was ten times that 
of colonoscopists with an ADR of greater than 20% 47. A large USA study found 
an inverse relationship between ADR and the risk of interval colorectal cancer, 
advanced-stage interval colorectal cancer and fatal interval colorectal cancer. A 
1% increase in ADR was associated with a 3% reduction in interval colorectal 
cancer and a 5% reduction in risk of a fatal interval colorectal cancer 62. If 
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results of the current trial mirrored this study, EV could potentially reduce the 
risk of interval colorectal cancer by 14% and fatal interval colorectal cancer by 
24%. 
 
The ADENOMA study was designed to check the efficacy of Endocuff Vision in 
ADR rather than cost effectiveness and therefore a formal economic analysis 
was not included. However, at a cost of £15 per device in the United Kingdom, it 
may provide a method of improving ADR which is simple, safe and well 
tolerated. 
 
5.4 Study limitations 
 
There are limitations to this study. Whilst the study was a randomised 
controlled trial, it could not be performed with operator blinding as the cuff 
was visible on insertion and the projections can be clearly seen holding back 
folds. Tandem studies have previously been used to compare devices in 
colonoscopy to identify missed lesions. However, a randomised controlled trial 
comparing ADR in two equivalent arms allowing for confounders is the optimal 
way to study this intervention. As this study compared ADR in both arms and 
both arms involved a single colonoscopy, missed adenomas are unlikely to have 
a significant impact on results. Although not stratified for or standardised, 
other interventions known to improve ADR were similar in the two groups. 
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Many studies purporting to demonstrate benefit of new technologies are 
conducted in expert (often single) centres. This study was undertaken in a 
mixture of academic and community settings and therefore results should be 
generalisable to standard clinical practice. Other studies have reported 
adenoma miss rate or other markers of quality but ADR is the most widely used 
and has been shown to correlate strongly with interval colorectal cancer rates 
and therefore has been chosen here as the primary outcome measure. 
 
5.5 A critique of thesis  
 
The aim of the study was to ascertain if there was a difference in adenoma 
detection rate between Endocuff Vision– Assisted Colonoscopy (EVAC) and 
Standard Colonoscopy (SC) patient groups and to quantify this by measuring 
ADR. Adenoma detection rate only identifies the percentage of procedures in 
which at least one adenoma is detected. Perhaps the more useful measure 
would have been to look at mean adenomas per procedure (MAP) which 
identifies the total number of adenomas detected divided by the number of 
procedures as it is more important to find and remove every adenoma present 
to reduce the risk of interval colorectal cancer and determine surveillance 
interval 47,49. 
 
  
 
154 
In the recent Dutch RCT investigating the relationship between Endocuff-
assisted colonoscopy and ADR, they found no difference between ADR in both 
groups but a significantly higher MAP in the Endocuff-assisted colonoscopy 
group 159. However, ADR is still currently the main marker of quality and used 
in most studies assessing quality in colonoscopy. In addition, ADR and MAP 
have been positively correlated in screening studies 44. In hindsight, there is a 
potential paradox in the way the outcome measures have been measured as in 
theory it is possible for one arm of the study to be inferior in ADR but superior 
in MAP. However, by evaluating both these indices, both arms of the study can 
be compared.  
 
The ADENOMA study was designed as a multicentre prospective randomised 
controlled trial which compared the performance of Endocuff Vision against 
standard colonoscopy in improving adenoma detection rate. It was conducted 
at multiple sites to reflect tertiary and secondary centres. Although a large-scale 
trial, it had a simple patient recruitment process. In addition, use of the 
Endocuff Vision did not unnecessarily lengthen colonoscopy time and no 
additional NHS resources were required. The ADENOMA study is a good 
example of collaboration between sites and illustrates that it is easy to recruit 
patients from BCSP. In addition, this study is less likely to have any known or 
unknown confounders as recruitment was completed very quickly. 
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The minimum of 20 training cases required for completion by each trial 
colonoscopists ensured that all colonoscopists had a minimum standard from 
which to progress from. However, it also contributed to a delay in initial patient 
recruitment. Particularly at the South Tees NHS Hospital site, the lead 
colonoscopist staggered the training of each participating colonoscopist, which 
resulted in low recruitment numbers in the initial months of the trial. This 
happened unbeknownst to the trial team and was only identified when I 
performed monitoring checks and enquired about the low recruitment 
numbers. Fortunately, this was swiftly corrected and all participating 
colonoscopists encouraged to start training immediately.  
 
The ADENOMA study was not a tandem study and therefore there is a 
possibility that some adenomas were missed. However, as this study compared 
adenoma detection rate in both arms and both arms of the study involve a 
single colonoscopy, missed adenomas are unlikely to have a significant impact 
on results.  
 
The study methods did not require standardisation of known quality 
improvement measures in colonoscopy. Colonoscopic withdrawal time of more 
than 6 minutes improves adenoma detection rate 63,166. In addition, the use of 
hyoscine-n-butylbromide 60,80, position change during colonoscopy 78 and rectal 
retroflexion 167 have been advocated to improve adenoma detection. This was 
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considered but it was felt that it would result in a study of a group of 
colonoscopists in a controlled environment and would not necessarily reflect 
real-life general practice of colonoscopists on a daily basis.   
 
One limitation of this study was that colonoscopists were not blinded to EVAC 
or SC groups. Therefore, this may have influenced colonoscopist behaviour 
through the Hawthorne effect. In addition, the presence of a research nurse in 
the room whilst the procedure was performed by the colonoscopist may also 
have resulted in more careful inspection of colonic mucosa and contributed to 
an elevated ADR. To combat this, alternatives were discussed which included 
having a different colonoscopist perform initial anal intubation or to video 
record each colonoscopy to be double read by a different colonoscopist after 
the procedure. However, this was felt to be impractical as the ‘finger-like’ 
projections of the Endocuff Vision occasionally came into luminal view during 
colonoscopy.  
 
In addition, it would have been useful to know what colonoscopists thought 
both objectively and subjectively about the use of Endocuff Vision. Therefore, 
we have arranged to conduct a further study by sending out questionnaires to 
colonoscopists to ask how they felt about the use of Endocuff Vision in their 
patients which will be in the next phase of the study.  
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In the ADENOMA study, the highest recruiting site was South Tyneside with 
538 patients followed by North Tees with 413 patients. This could reflect that 
these sites were more motivated to recruit patients and therefore potentially 
more sensitive to finding adenomas and increasing ADR. However, in South 
Tyneside, 147 number of participants were recruited by surgeons with lower 
than average ADRs.  
 
Another source of bias in this study is the experience of each colonoscopist. 
This was not standardised in the study and we did not ask information 
regarding years of experience or previous number of colonoscopies performed. 
With hindsight, this should have standardized this as colonoscopist related 
factors can affect ADR and quality of colonoscopy. On the other hand, by 
taking ‘all comers’, this may be a better reflection of the general population. 
 
Whilst this study stratified for the BCSP subgroup in both arms, the proportion 
of patients overall recruited as BCSP and non-BCSP was not mandated. Thus, 
the recruitment of BCSP and non-BCSP patients differed from the anticipated 
80/20 ratio. Over-recruitment in the BCSP population occurred due to the 
optimal research environment in BCSP with research interested clinicians and 
nurses.  
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Lastly, the ADENOMA study was designed to check the efficacy of Endocuff 
Vision in ADR rather than cost effectiveness and therefore a formal economic 
analysis was not included. However, at a cost of £15 per device in the United 
Kingdom, it may provide a method of improving ADR which is simple, safe and 
well tolerated.   
 
5.6 Issues with recruitment  
 
All patients were recruited consecutively and were only excluded from the 
study if they fulfilled the exclusion criteria or if they did not consent to study 
participation. 
 
However, on 26 May 2015 as part of a statistical periodic review of the 
randomisation system, NWORTH observed that several changes were made to 
the randomisation system. NWORTH IT were instructed to not make any 
further changes to the system until the change had been discussed and agreed 
with the trial management team. I carried out an internal investigation and 
found that in 9 instances there was a removal of randomisation. The details of 
each removal of randomisation are illustrated in Table 35.  
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Site Patient ID  Reasons 
South Tyneside 101167 Patient was on anticoagulation and this was only 
discovered when patient was in endoscopy room 
before procedure was performed.   
101076 This patient ID number had been used twice in error 
101180 This patient was not eligible to participate in the 
study due to being age 17. 
North Tees 616840  The wrong patient ID number was entered. This was 
meant to be 671139. 
St Marks 215008 Patient randomised twice in error. 
215076 Wrong birth date entered. 
South Tees 443014 Patient found to be on warfarin so not eligible.  
443019 Patient was too unwell for colonoscopy so 
procedure was rearranged. This patient should have 
been included in the study instead of being removed 
and this was treated as a protocol deviation. 
443020 Patient had a poor result from bowel preparation so 
procedure was rearranged. This patient should have 
been included in the study instead of being removed 
and this was treated as a protocol deviation. 
 
Table 35: Issues with recruitment 
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Table 35 illustrated that in two cases – patient 443019 and 443020, there was a 
protocol deviation from the study. The research nurses at South Tees Hospital 
were informed immediately about the error and underwent further training to 
ensure this did not happen again.  
 
In addition, all research nurses and principal investigators were informed of 
these events during the Gastrointestinal Clinical Research Network meeting on 
4th June 2015 and reminded that such patients should be included on a 
‘intention to treat’ basis. All sites were advised to only randomise patients in 
the endoscopy room to avoid any last-minute changes.  In addition, any further 
requests for removal of randomisations from NWORTH were monitored and 
discussed with me to prevent any further similar violations. The randomisation 
algorithm was also corrected to disallow patients under the age of 18 from being 
recruited. 
 
5.7 Reflections from undertaking thesis  
 
The experience of starting and then completing this thesis has been an 
informative and interesting journey to say the least. I have learnt and picked up 
many skills along the way and continue to do so. I have found this journey 
challenging at times but having an interesting and relevant research topic 
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coupled with a wonderful research unit has made my out of programme 
research experience fulfilling and enjoyable.  
  
In completing the literature review for this thesis, I have developed my ability 
to review and critically appraise medical literature. I have also gained a clearer 
understanding of basic research principles and I am more confident with 
research methodology and basic statistics.  Due to the nature of this thesis, I 
have a much greater knowledge and understanding of the importance of 
detecting and removing colorectal adenomas and the various methods and 
devices available to me to achieve this. This will stand me in good stead in my 
career as a colorectal surgeon.   
 
I am confident that the results of the ADENOMA study will make a significant 
contribution towards improving quality in colonoscopy and provide the 
groundwork for other studies. I hope that, in time, the results of this study will 
contribute towards reducing morbidity and mortality from colorectal cancer.  
 
Lastly, I have found setting up and running a multicentre RCT extremely 
rewarding and plan to continue to be active in academia and research. 
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5.8 Suggestions for further work  
 
This study has shown that Endocuff Vision significantly improves the detection 
of left colon adenomas by 3.9%. In particular, there were significant 
improvements in the detection of 6-9mm and ≤5mm adenomas with EVAC. 
This suggests that Endocuff Vision may have a role to play in the NHS Bowel 
Scope screening (BSS) programme. The BSS programme began in 2013 and 
offers all men and women in England a one-off flexible sigmoidoscopy. The aim 
of the BSS programme is to reduce colorectal cancer development via the 
adenoma-carcinoma sequence through the detection and removal of adenomas 
from the left side of the colon. However, ADR is not as high as expected in BSS 
patients compared to the NHS BCSP with national BSS ADR reported at 9.2% 72. 
In addition, there seems to be a significant ADR variation of 7-12% between BSS 
endoscopists 72 . The reasons for variation can be extrapolated from 
colonoscopy data and include poor technique, shorter withdrawal time, 
inadequate bowel preparation, the presence of flat or subtle lesions, the 
inability to visualise the proximal side of haustral folds, blind spots in flexures, 
and rectal or ileocaecal valves 57,58. However, in the BSS population, it is 
difficult to implement measures such as better bowel preparation, using anti-
spasmodics or lengthen withdrawal time without increasing patient risk or 
discomfort.  
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Interventions to improve ADR such as the utilisation of adjuncts like Endocuff 
Vision may offer a safe way of improving ADR. Attachment of Endocuff Vision 
can slightly increase anal irritation on anal intubation but emphasis on 
adequate lubrication and careful insertion will ensure that discomfort is kept to 
a minimum.  As a result of the findings in the ADENOMA study, a multicentre 
randomised controlled trial into the use of Endocuff Vision in NHS Bowel 
Scope participants is currently underway. This study has been called the B-
ADENOMA (BowelScope: Accuracy of Detection using Endocuff Optimisation 
of Mucosal Abnormalities) study.  
 
In addition, a head-to-head comparison of Endocuff Vision with other devices 
such as cap-assisted colonoscopy or EndoRings will be beneficial in assessing 
the best and safest device to improve ADR. Lastly, it may be appropriate that 
large multicentre RCT’s utilise MAP as their primary study outcome instead of 
ADR as it is becoming clearer that it is more important to detect and remove all 
adenomas.  
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Appendix 1: Case Report Form 
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Appendix 2: Next Day Questionnaire  
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Appendix 3: 21-day review form  
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